

# BMJ Open

## Keeping Weight Off: Brain Changes Associated with Healthy Behaviors: Study Protocol of a Randomized Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-012573
Article Type:	Protocol
Date Submitted by the Author:	09-May-2016
Complete List of Authors:	Fulwiler, Carl; University of Massachusetts Medical School, Center for Mindfulness; Siegel, Julia Allison, Jeroan Rosal, M; University of Massachusetts , Medicine Brewer, Judson; Center for Mindfulness King, Jean; Psychiatry, Neurology, Radiology
<b>Primary Subject Heading</b>:	Complementary medicine
Secondary Subject Heading:	Medical management
Keywords:	mindfulness, weight loss, behavior change maintenance, neuroimaging

SCHOLARONE™  
Manuscripts

**TITLE PAGE**

Keeping Weight Off: Brain Changes Associated with Healthy Behaviors:  
Study Protocol of a Randomized Controlled Trial

Carl Fulwiler<sup>1</sup>, Julia A. Siegel<sup>2</sup>, Jeroan Allison<sup>3</sup>, Milagros C. Rosal<sup>4</sup>, Judson Brewer<sup>1</sup>, Jean A. King<sup>5</sup>

<sup>1</sup> University of Massachusetts Medical School, Departments of Psychiatry and Medicine and Center for Mindfulness

<sup>2</sup> University of Massachusetts Medical School

<sup>3</sup> University of Massachusetts Medical School, Department of Quantitative Health Sciences

<sup>4</sup> University of Massachusetts Medical School, Department of Medicine

<sup>5</sup> University of Massachusetts Medical School, Departments of Psychiatry, Neurology and Radiology

**Corresponding Author (Primary Sponsor):**

Carl Fulwiler, MD, PhD

Center for Mindfulness

University of Massachusetts Medical School

222 Maple Avenue

Shrewsbury, MA 01545

Email: [carl.fulwiler@umassmed.edu](mailto:carl.fulwiler@umassmed.edu)

Phone: +1 508-856-8389

Fax: +1 508-856-1977

**Keywords:**

mindfulness; Mindfulness Based Stress Reduction; weight loss; behavior change maintenance; resting state functional connectivity; neuroimaging

**Word count: 3,955**

**ABSTRACT (300 words)****Introduction:**

Obesity is a growing epidemic fueled by unhealthy behaviors and associated with significant comorbidities and financial costs. Weight loss is vital to mitigate these burdens but, while behavioral interventions produce clinically meaningful weight loss, weight loss maintenance is challenging. This may partially be due to failure of interventions to target stress and emotional reactivity and their potential impact on relapse to unhealthy behaviors. Mindfulness-Based Stress Reduction (MBSR), a psycho-educational program that teaches emotional and physical self-care, effectively reduces stress and emotional reactivity and may be a useful tool for behavior change maintenance. This study seeks to provide a mechanistic understanding for clinical trials of the benefits of MBSR for weight loss maintenance by examining changes in functional connectivity in an emotion regulation circuit and the association of these changes with clinical outcomes.

**Methods and analysis:**

Community-dwelling individuals (n=80) who intentionally lost  $\geq 5\%$  of their body weight in the past year will be recruited and randomized to an MBSR program or educational control. Functional connectivity (FC) using resting state functional MRI (fMRI) will be measured at baseline and 8 weeks. Psychological factors, health behaviors, body mass index (BMI), and waist circumference will be measured at baseline, 8 weeks, and 6 months post-intervention. A 12-month telephone follow-up will assess self-reported weight. Analyses will characterize FC changes in response to MBSR in comparison to a control condition, assess the relationship between baseline FC status and pre-post MBSR changes in FC, and investigate the association of FC change with changes in psychological factors and weight loss maintenance.

**Ethics and dissemination:**

The University of Massachusetts Medical School Institutional Review Board has approved this study, Declaration of Helsinki protocols are being followed, and patients will give written informed consent. The Independent Monitoring Committee will monitor protocol adherence.

**Trial registration number:** NCT02189187 (<http://clinicaltrials.gov>).

## ARTICLE SUMMARY

### Article focus

- How does MBSR affect functional connectivity (FC) in emotion regulation circuits and are specific changes in FC related to improved ability to maintain weight loss?
- Can we identify a stable change in brain circuitry (a biomarker) that corresponds with lasting effects of MBSR?
- Can we use this biomarker to monitor fidelity of intervention delivery, adherence, and dose-response in future clinical trials?

### Key messages

- Many tools are effective for *initiating* health behavior change such as weight loss, but study results may suggest that MBSR could be effective for *maintenance* of health behavior change, which would be instrumental in decreasing rates of obesity and associated comorbidities.
- If successful, this study will demonstrate that MBSR alters resting state connectivity in emotional regulation circuitry, and that these changes can serve as a valuable biomarker and predictor of long-term maintenance of healthy behaviors.
- This biomarker may allow future studies to identify which components of the mindfulness intervention are most active, and which individuals are most responsive, and may enable development of a more compact and potent intervention that can be tailored toward response optimization based on individual differences.

### Strengths and limitations of this study

- This is a timely and innovative study that will advance the field of mindfulness research and increase understanding of its mechanisms of action, setting the stage for a comprehensive clinical trial.
- The intervention is low-risk, highly accessible, low-cost, and is implemented in a real world clinical population and community setting. The control course was specifically designed to serve as an attention control for MBSR.
- The cost of a neuroimaging biomarker could be considered a limitation for large-scale clinical trials, but the insights about neural mechanisms of change cannot be obtained with other methods.

## INTRODUCTION

Unhealthy behaviors such as overeating and sedentary lifestyles are major contributors to cardiovascular disease, cancer, type 2 diabetes and other chronic conditions. They have produced a rapid rise in obesity that threatens to reverse recent gains in life expectancy<sup>1</sup> and accounts for a large percentage of premature deaths in the U.S.<sup>2</sup> The number of obese adults in the U.S. is expected to rise by 65 million from 2010 to 2030, resulting in a predicted additional 6–8 million cases of diabetes, 5–6.8 million cases of heart disease and stroke, and over 400,000 cancer cases.<sup>3</sup> For each 5kg/m<sup>2</sup> increase in BMI, the risks of esophageal cancer and colon cancer in men increase by 52% and 24%, respectively, and the risks of endometrial cancer, gall bladder cancer, and breast cancer in women increase by 59%, 59%, and 12%, respectively.<sup>4</sup>

In addition to significant morbidity, obesity has a substantial financial impact due to both health care costs and decreased productivity. Obesity-related U.S. health care costs were \$2.5 trillion in 2009 and are predicted to rise by at least \$22 billion/year by 2020 and \$48 billion/year by 2030.<sup>3</sup>

Weight loss is vital for reducing these extensive health and economic burdens; and even minimal weight loss has a meaningful impact. In an overweight and obese population in Ireland, a 1kg/m<sup>2</sup> decrease in BMI led to 26 fewer cases of chronic disease per 1,000 men and 28 fewer cases per 1,000 women.<sup>5</sup> Similarly, a 1% decrease in BMI across the U.S. population (1kg weight loss for the average adult) is predicted to prevent 2.1–2.4 million cases of diabetes, 1.4–1.7 million cases of cardiovascular disease, and 73,000–127,000 cancer cases; and would only require reducing caloric intake by 20 kcal per day for 3 years.<sup>3</sup>

Current obesity treatments include lifestyle modification, pharmacotherapy, and surgical options. A systematic review of various approaches to weight loss maintenance found that behavioral interventions involving both food intake and physical activity led to significant, albeit small, improvements in weight loss maintenance at 12 months after the intervention.<sup>6</sup> Exercise programs alone, however, may be most effective in the adoption phase.<sup>7</sup> Similarly, certain medications such as orlistat and sibutramine facilitate weight loss but commonly only work short-term when used alone, and may have unfavorable side effects.<sup>8</sup> Bariatric surgery can be effective long-term, but it can be associated with perioperative surgical risks and weight regain is common.<sup>8</sup> Also, many patients are unwilling or ineligible to undergo surgery.

Many interventions are effective for initiating weight loss and other health behavior changes, but they have shown only limited ability to affect significant, long-term behavior change in the majority of adults.<sup>7,9–11</sup> In part this may be attributable to a failure of existing interventions to adequately address the effects of stress and emotional reactivity on relapse to unhealthy behaviors and failure to maintain long-term behavior change. Perceived stress and symptoms of emotional reactivity (depression, anxiety, anger) are linked to unhealthy lifestyle behaviors<sup>12–15</sup> and predict worse outcomes in maintenance studies.<sup>16–18</sup> Indeed, studies of health behavior change have demonstrated that perceived stress<sup>19–21</sup> and indices of emotional reactivity such as anxiety,<sup>22–24</sup> depression, and anger<sup>25–27</sup> are associated with poor outcomes. In contrast, positive affect is associated with improved outcomes.<sup>28,29</sup>

1  
2  
3 Mindfulness, defined as paying attention to one's inner and outer experiences in a non-  
4 judgmental manner from moment to moment,<sup>30</sup> has been associated with healthy behaviors.  
5 Dispositional mindfulness in obese patients awaiting bariatric surgery was found to be positively  
6 associated with a restrained eating style (using restrictive control over food to lose weight) but  
7 negatively associated with emotional (eating in response to emotional states) and external eating  
8 behaviors (eating in response to external cues). Mindfulness may discourage external eating by  
9 increasing sensitivity to hunger and satiety such that these internal cues guide behavior instead.  
10 In addition, mindfulness may prevent emotional eating by encouraging acceptance of negative  
11 feelings, lowering stress, and thus promoting distinction between emotion and hunger. Finally,  
12 mindfulness has been shown to decrease impulsivity which may reduce unhealthy eating  
13 behaviors.<sup>31</sup>  
14  
15  
16

17  
18 Several mindfulness-based or mindfulness-associated practices are promising agents of behavior  
19 change, but we need to understand their neural mechanisms in order to optimize their use.  
20 Mindfulness-Based Stress Reduction (MBSR) is a psycho-educational program that teaches  
21 emotional and physical self-care. Participants receive training in formal and informal  
22 mindfulness practices and learn about the role of good nutrition, rest, and exercise, as well as the  
23 role played by thoughts and emotions in physical and emotional health. They are taught how to  
24 cultivate a non-reactive awareness of mental and physical experience in an effort to increase self-  
25 efficacy and reduced emotional reactivity—leading to healthier lifestyle practices. A recent  
26 comparative effectiveness review found moderately strong evidence for mindfulness meditation  
27 programs, particularly MBSR, for anxiety, depression and pain compared to nonspecific active  
28 controls, and weaker evidence for stress and health-related quality of life.<sup>32</sup> Evidence is mixed  
29 regarding the effectiveness of mindfulness-based interventions on weight loss, at least with  
30 relatively short follow-up periods.<sup>33</sup> Whether MBSR can support maintenance of weight loss  
31 following successful initiation of health behavior change warrants investigation based on its  
32 ability to lower emotional and behavioral reactivity to stress and negative emotions, risk risk  
33 factors for relapse to unhealthy behaviors. Importantly, an understanding of neural targets and  
34 mechanisms of change is necessary for specifying for whom mindfulness is likely to work and  
35 for optimizing the intervention for maximal effectiveness. Mindfulness may work better in  
36 specific subpopulations, as seen in a group of women with specific endogenous opioidergic  
37 activity who were found to be more receptive to mindfulness training in an effort to decrease  
38 pleasure eating.<sup>34</sup> Additionally, efficacy of mindfulness-based therapy has been strongly  
39 positively associated with dispositional mindfulness of participants and therapists.<sup>35</sup>  
40 Neuroimaging, specifically resting state functional MRI (fMRI), is a powerful approach to  
41 identifying mechanisms of change for MBSR involving the role of emotion regulation in  
42 maintenance of health behavior change.  
43  
44  
45  
46  
47

48  
49 Neuroimaging studies report an association between MBSR and changes in functional  
50 connectivity (FC) that may reflect improved attention, sensory processing, and reflective  
51 awareness of sensory experience.<sup>36,37</sup> Mindfulness has also been shown to alter resting state FC  
52 of the amygdala, a region involved in physiological stress response. A randomized controlled  
53 trial found that a three-day intensive mindfulness training reversed the effects of stress on the  
54 amygdala-subgenual anterior cingulate cortex in a group of stressed unemployed adults in the  
55 community.<sup>38</sup> This mindfulness training was also shown to increase resting state FC between the  
56 default mode network and the left dorsolateral prefrontal cortex, an area involved in top-down  
57  
58  
59  
60



executive control.<sup>39</sup> However, no previous studies have examined how mindfulness training affects the neural circuitry of emotion regulation in a weight loss sample and little is known about mechanisms of behavior change in people undergoing mindfulness training.

### Gaps in knowledge

Emerging evidence suggests that mindfulness may be helpful for changing behaviors such as overeating<sup>40</sup> but the mechanistic knowledge of how mindfulness facilitates behavior change is not known. Efforts to fill this gap could enhance our ability to identify likely “responders” and thus optimize intervention efforts, consistent with current trends towards personalized medicine approaches. Specifically, we are lacking knowledge of specific neural targets of mindfulness training to inform clinical trials of health behavior change and maintenance of change. In addition, data on long-term outcomes of mindfulness training is lacking.

Understanding the neural mechanisms that link MBSR to changes in emotional regulation and behavior are a critical next step in tapping the potential of MBSR as an intervention for behavior change and maintenance. A validated biomarker will allow investigators to monitor fidelity of intervention delivery, adherence, and dose-response in clinical trials. If validated as a biomarker, changes in FC will allow future studies to determine characteristics of individuals who are most responsive to MBSR and which components of the mindfulness intervention are most active, and may enable development of a more compact and potent intervention. FC may also help identify subsets of high-risk patients that would benefit from specific tailoring of the intervention. It is worth noting that if clinical trials prove that MBSR prevents weight regain, MRIs would not be required in a larger dissemination study or as the intervention is deployed in a large-scale public health approach.

### Study aims and hypotheses

To characterize FC, psychological, behavioral, and anthropometric changes in response to MBSR and the comparison condition, we will randomize a sample of 80 participants who have intentionally lost  $\geq 5\%$  of their body weight during the previous year to MBSR or an attention control specifically designed to be structurally equivalent to MBSR. Study aims and hypotheses are as follows.

Our first primary aim is to characterize FC changes in response to MBSR and the comparison condition. We hypothesize that participants randomized to the MBSR condition will experience greater increases in FC from baseline to post-intervention (Hypothesis 1); and participants with higher baseline FC will show less change in response to MBSR (Hypothesis 2).

Our second primary aim is to investigate the association of FC change with changes in psychological factors and maintenance of weight loss at 8 weeks and 6-month follow-up. We hypothesize that increases in FC will be associated with improvement in depressive symptoms (Hypothesis 3) and inversely related to decreased weight (BMI) and total waist circumference (Hypothesis 4).

Our third primary aim is to assess **changes in BMI at 6 & 12 months to obtain preliminary measures of effect size and variability by study group for future clinical trials.**

1  
2  
3 As secondary aims, we will use mediation analysis to determine how change in FC is explained  
4 by 1) class attendance, 2) self-reported time in homework practice, 3) self-reported time for each  
5 specific component of the multifaceted training program, and 4) trait mindfulness. An  
6 exploratory aim is to examine correlations of change in FC with changes in additional  
7 psychological factors (perceived stress, trait anger, trait anxiety, positive affect) and health  
8 behaviors (healthy eating, physical activity, sleep quality).  
9  
10

## 11 METHODS

### 14 Study design

15 The “Keeping Weight Off” study is a randomized, prospective, two-armed, controlled trial. A  
16 sample of 80 participants from the community, who have intentionally lost at least 5% of their  
17 body weight during the previous year, will be equally randomized into two groups: an MBSR  
18 program and a Healthy Living Course (HLC)—an attention control specifically designed to be  
19 structurally equivalent to MBSR.<sup>41</sup> The HLC uses the same format of 8-weekly classes lasting 2  
20 1/2 hours, and controls for attention and other nonspecific factors including staff interactions,  
21 psychoeducation about health and stress management, classroom format, homework, group  
22 process, and data collection.<sup>41</sup> Our main outcome measures are resting-state FC, depression  
23 symptoms, BMI, and waist circumference. FC, psychological factors, health behaviors, BMI, and  
24 waist circumference will be measured at baseline and 8 weeks. Psychological factors, health  
25 behaviors, BMI, and waist circumference will also be measured at 6 months. In addition, a  
26 telephone follow-up will be attempted on participants at 12 months to assess weight.  
27  
28  
29

30 Total planned enrollment is 80 participants. Screening for eligibility criteria, baseline visits, and  
31 follow-up visits will take place at University of Massachusetts Medical School (UMMS),  
32 Worcester, Massachusetts. All MBSR classes will be conducted at the UMMS Center for  
33 Mindfulness in Shrewsbury, Massachusetts.  
34  
35

### 37 Study participants

38 We will recruit participants who range in age from 25 to 60 (chosen to minimize age-related  
39 changes in FC), have intentionally lost  $\geq 5\%$  of their body weight during the previous year, and  
40 are motivated to maintain this weight loss. Individuals will be excluded if they have participated  
41 in an MBSR course, regular meditation practice, or any other form of meditative practice (such  
42 as yoga, Tai Chi or contemplative prayer), for more than an average of 20 minutes per week  
43 within the past 2 years. Full inclusion and exclusion criteria are listed in Table 1.  
44  
45

46 Eligible participants will proceed with the baseline visit prior to randomization, including  
47 collection of demographic information about age, education, marital status, occupation, and  
48 current employment status, followed by questionnaires and fMRI scan. All participants will  
49 provide informed consent. This process will be conducted by the study coordinator in person  
50 prior to the baseline visit, following the protocol established by the University of Massachusetts  
51 Institutional Review Board (IRB). Study staff will keep in touch with participants regarding  
52 attendance and homework completion and provide support and encouragement to continue with  
53 the intervention if participants express dissatisfaction. Participants who drop out of the  
54 intervention will be asked to return for all follow-up visits to complete all outcome data  
55 collection.  
56  
57  
58  
59  
60



## Study recruitment

Recruitment will be conducted using advertising in the community (internet, flyers and social media) as well as a two-stage process to recruit outpatients from the UMass Memorial Medical Center using the electronic medical record. First, with a HIPAA waiver authorization a search query will be conducted with basic eligibility criteria, and secondly identified records will be reviewed to exclude causes of weight loss such as serious illness or weight loss medications. Web-based and telephone screening will determine whether they meet inclusion criteria. Further screening will be done in person to gather a medical history and complete the Structured Clinical Interview for DSM-IV (SCID) to exclude participants with a serious psychiatric, cognitive or medical disorder or a history of alcohol or substance abuse or dependence in the past 6 months.

## Randomization and study blinding

Study participants will be equally randomized to either the MBSR intervention arm or HLC arm based on a permuted blocks randomization scheme. In this procedure, treatment allocations will be made within blocks so that the numbers assigned to each arm are equal after each block has been filled. Blocks of various sizes (2, 4, 6) will be used in random order, to facilitate allocation concealment, that is, to make it nearly impossible to determine the treatment assignment based on a pattern of previous treatment allocations. Randomization will be implemented by the study coordinator using sealed envelopes.

To address the possibility that an imbalanced distribution of baseline FC could mask important findings, we will employ a non-stratified permuted-block randomized design with an interim analysis of the distribution of baseline FC. If important imbalances are found, we will implement recruitment strategies to increase enrollment of participants who have baseline FC with a specified range combined with covariate-adaptive randomization techniques. Residual imbalances will be addressed with post-hoc statistical adjustment.

## Assessments

### *Resting state functional connectivity*

All MRI's will be acquired on the 3T scanner (Philips Achieva) in the UMMS Advanced MRI Center. 3D high-resolution structural T1-weighted MR images will be obtained to provide anatomical landmarks. Following the structural imaging, resting-state fMRI data will be collected. Participants will be instructed to remain relaxed with eye closed as fMRI images are continuously collected for 10 mins. The duration of the entire MRI procedure will be 30 min.

### *Psychological symptoms*

The Center for Epidemiologic Studies Depression Scale (CES-D)<sup>50</sup> depression symptom score is a primary outcome. Additional outcomes include perceived stress, anxiety, anger, positive affect, and emotion regulation, which will be assessed using the following measures respectively: the Perceived Stress Scale (PSS-14),<sup>51</sup> the State-Trait Anxiety Inventory – trait version (STAI-T),<sup>52</sup> the State-Trait Anger Expression Inventory (STAXI-II) trait anger subscale,<sup>53</sup> the Satisfaction with Life Scale<sup>54</sup> and the Emotion Regulation Questionnaire.<sup>55</sup>

### *Health behaviors*

1  
2  
3 Health behaviors will be assessed using the Eating Behavior Inventory,<sup>56</sup> the Internal  
4 Disinhibition Subscale of the Eating Inventory,<sup>57</sup> the Paffenbarger Physical Activity Scale,<sup>58</sup> and  
5 the Pittsburgh Sleep Quality Index (PSQI),<sup>59</sup> respectively.  
6  
7

### 8 *Anthropometrics*

9 Procedures are adapted from the CDC's Anthropometry Procedures Manual.<sup>60</sup> For the  
10 measurement of height and weight, the Seca 213 Portable stadiometer and the TANITA, BWB-  
11 800 electronic scale will be used and measurements will be taken twice and averaged to assure  
12 reliability. Measurement of waist circumference will be taken directly on the skin using  
13 measuring tape placed just above top of the iliac crest on each side.  
14  
15

### 16 **Potential mediators and confounds**

17 Intervention engagement will be assessed with class attendance and a home practice log.  
18 Treatment expectancy and credibility will be assessed with the Credibility/Expectancy  
19 Questionnaire CEQ<sup>61</sup> modified slightly to substitute the word "Class" for "Therapy" in the  
20 instructions. Secondary analyses will examine how change in FC is explained by 1) class  
21 attendance, 2) self-reported time in homework practice, 3) self-reported time for each specific  
22 component of the multifaceted training program, and 4) trait mindfulness as measured by the  
23 Five Facet Mindfulness Questionnaire (FFMQ).<sup>62</sup>  
24  
25  
26

### 27 **Interventions**

#### 28 *Experimental Condition: Mindfulness-Based Stress Reduction (MBSR)*

29 MBSR, described above, is taught in eight weekly classes and one all-day retreat. Homework  
30 assignments include formal meditation practices and informal practices during daily life.  
31 Classroom activities teach formal meditation practices including sitting meditation, body scan,  
32 mindful yoga, walking meditation). Participants also learn to bring awareness in the present  
33 moment to aspects of daily life and apply this practice to stressful experiences in order to avoid  
34 reflexive or conditioned reactions. The goal of MBSR is to provide participants with these skills  
35 for lifelong self-management.  
36  
37  
38

39 The MBSR classes are taught by certified teachers from the UMass Center for Mindfulness. All  
40 teachers have completed the rigorous training and certification for MBSR through the Center for  
41 Mindfulness. To further assure fidelity each class will be reviewed in weekly sessions with a co-  
42 investigator. In addition, the principal investigators will routinely convene the entire clinical  
43 research team to monitor the overall fidelity of the MBSR intervention.  
44  
45

#### 46 *Attention control: Healthy Living Course*

47 The Healthy Living Course (HLC) was specifically designed to serve as a control condition for  
48 MBSR.<sup>41</sup> HLC consists of 8 weekly 2-hour classes. Sessions consist of lectures and discussion  
49 on the following topics: healthy living, healthy eating, physical activity and health, sleep and  
50 health, stress management, time management, and unhealthy behaviors (smoking, drinking). The  
51 HLC is designed to control for attention and other nonspecific factors including staff  
52 interactions, psychoeducation about health and stress management, classroom format,  
53 homework, group process, and data collection.<sup>41</sup>  
54  
55

### 56 **Data collection**

57  
58  
59  
60

1  
2  
3 Electronic data capture (EDC, REDCap<sup>TM</sup>) will be used for all data collection except imaging.  
4 Surveys for psychological symptoms, health behaviors, and potential mediators and confounds  
5 are programmed into the EDC system. During research visits, participants will enter survey  
6 responses directly into this system and research staff will enter screening and anthropometric  
7 data with periodic checks for quality assurance. All data will be maintained in a secure location  
8 accessible only to study personnel. For MRI measures, data will be analyzed blind to  
9 intervention group by two fMRI experts who perform cross-validity checks.  
10  
11

### 12 **Data analysis and sample size considerations**

14 We based the study sample size on Hypothesis 1, powered to detect an effect size of 0.32  
15 standard deviations. This moderate Cohen effect size<sup>63</sup> represents differential over-time change  
16 for the intervention versus comparison group cast in standard deviation units. The study design  
17 calls for a baseline measurement and two follow-up measurements. In addition, we assumed a  
18 two-tailed alpha error of 0.05, and a within-person correlation for over-time measurement of  
19 0.8.<sup>64</sup> With these assumptions, 40 participants in each group are needed for 80% power. We will  
20 enroll 100 participants (50 randomized to each arm) and allow for up to 20% loss to follow up,  
21 for an effective sample size of 80.  
22  
23

24  
25 Statistical analysis will begin with univariate summaries of data distributions and examination of  
26 longitudinal trends with graphic displays. Bivariate associations will then be examined using the  
27 chi-square test, ANOVA, and the Spearman correlation test. Hypotheses 1 and 2 focus on over-  
28 time differences between the two study groups, while Hypotheses 2 and 3 focus on over-time  
29 differences for the combined sample. Hypotheses will be formally tested using generalized linear  
30 mixed models that represent the clustering of observations within participants as a random  
31 intercept, adopt an appropriate link and distribution for the specific outcome, and parameterize  
32 the intervention effect as a group-time intervention, when appropriate.<sup>65</sup> To preserve the power  
33 of randomization, hypothesis testing will be performed on an intent-to-treat basis. As a  
34 secondary aim, mediation analysis will determine how change in FC is explained by markers of  
35 intervention adherence using techniques as described by MacKinnon.<sup>66,67</sup> Sensitivity analyses  
36 with multiple imputation with chained equations will address missing data.  
37  
38

39  
40 Imaging data is preprocessed using Statistical Parametric Mapping (SPM8) software (Wellcome  
41 Department of Cognitive Neurology, London, UK) running under the MATLAB environment  
42 (Mathworks, Inc., Sherborn, MA). The data is initially corrected for motion (threshold of 2 mm).  
43 Further pre-processing of the data includes a) slice scan time correction, b) spatial smoothing  
44 using a 3D Gaussian filter (4-mm FWHM), and c) voxel-wise linear detrending and 0.01-0.08Hz  
45 band-pass filtering. Structural and functional data of each participant is then be transformed to  
46 standard stereotaxic space<sup>68</sup> to facilitate group analysis.  
47  
48

49  
50 Following the preprocessing steps, FC will be generated using correlational analysis. Left and  
51 right amygdala are used as separate seed regions of interest (ROI). FC maps from each individual  
52 seed will then be calculated for each individual subject using Resting-State fMRI Data Analysis  
53 Toolkit (REST, <http://www.restfmri.net>). Each seed ROI will be evaluated using two-way  
54 repeated measures ANOVA on a voxel-by-voxel basis (factors: group and imaging day) at the  
55 threshold of  $p < 0.05$  after accounting for multiple comparisons using the criteria of false  
56 discovery rate (FDR).<sup>69</sup> Voxels with significantly changed FC within each ROI will then be  
57  
58  
59  
60

1  
2  
3 averaged to generate the FC change for the ROI. This procedure will yield a single value of  
4 amygdala-orbitofrontal FC for each participant at each point in time. All ROI definitions are  
5 based on Automated Anatomical Labeling (AAL)<sup>70</sup> built in the MarsBAR toolbox of SPM8.  
6 Image analysis will be done blind to group membership.  
7  
8

9  
10 As a secondary analysis, we will explore FC changes in other brain networks following MBSR  
11 using other seed regions. For example, other cortical regions that have been implicated in  
12 modulation of limbic reactivity (e.g. anterior cingulate) will be examined using a hypothesis-driven  
13 approach.  
14

### 15 **Ethical considerations**

16 This study is approved by the University of Massachusetts Medical School IRB and registered as  
17 a national clinical trial (NCT02189187), Declaration of Helsinki protocols are being followed,  
18 and patients will give written informed consent. Protocol adherence will be monitored by the  
19 Independent Monitoring Committee.  
20  
21

### 22 **AUTHORS' CONTRIBUTIONS**

23 CF conceptualized the study, and JAK, JA, MR and JB participated in the study design. CF,  
24 JAK, and JAS collected data. CF and JAS wrote and all authors revised the article and approved  
25 the final version to be published.  
26  
27

### 28 **COMPETING INTERESTS**

29 All authors declare no conflicts of interest.  
30  
31

### 32 **ACKNOWLEDGEMENTS**

33 The authors thank Dr. Nanyin Zhang and Dr. Wei Huang for technical assistance with study  
34 design. We also extend our sincere gratitude to Dr. Saki Santorelli, Executive Director of the  
35 Center for Mindfulness at the University of Massachusetts Medical School, for his support and  
36 contributions, and the staff and teachers of the Center for Mindfulness for their assistance. The  
37 project was conducted at the UMMS Advanced MR Imaging Center with support from Dr.  
38 Shaokuan Zheng.  
39  
40

### 41 **FUNDING**

42 The National Center for Complementary and Integrative Health (NCCIH) provided funding for  
43 this trial (grants R34AT006963 and R34 AT006963-01A1 to CF and JAK). The design of this  
44 trial was reviewed and approved by NCCIH's Office of Clinical and Regulatory Affairs. Support  
45 was also provided by an award from the UMMS Department of Radiology. The content is solely  
46 the responsibility of the authors and does not necessarily represent the official views of the  
47 National Institutes of Health or the UMMS Department of Radiology Advanced MR Imaging  
48 Center.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TABLES

Table 1. Eligibility criteria

<u>Inclusion criteria:</u>	<u>Exclusion criteria:</u>
<ul style="list-style-type: none"> <li>• Males and females</li> <li>• Right or left handed</li> <li>• Ages 25-60</li> <li>• Intentionally lost <math>\geq 5\%</math> of body weight during the previous year</li> <li>• Intending to maintain weight loss</li> <li>• BMI &gt; 25 kg/m<sup>2</sup> in the past 2 years and greater than 20.5 kg/m<sup>2</sup> at time of study entry</li> <li>• Under the care of a primary care physician for at least the last year prior to screening</li> <li>• Able to communicate by telephone with research staff</li> <li>• Have a healthcare provider, personal trainer or weight-loss counselor who can complete and sign a form indicating the amount and timing of their weight loss OR have a dated photograph or weight loss diary.<sup>71</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Weight &gt;300lbs (limitation of MRI scanner)</li> <li>• Prior participation in an MBSR course</li> <li>• Regular meditation practice (or any other form of meditative practice, such as yoga, Tai Chi, or contemplative prayer) for more than an average of 20 min/week within the past 2 years</li> <li>• Serious psychiatric, cognitive, or medical disorder</li> <li>• Alcohol/substance abuse or dependence in past 6 months</li> <li>• Any conditions that are incompatible with MRI</li> <li>• Structural brain damage as determined by an independent neuroradiologist, based on T1W 3D TFE sagittal and T1W FFE axial images</li> <li>• History of an eating disorder, diabetes mellitus or medications for diabetes mellitus</li> <li>• Medication that affects weight (weight loss medications, corticosteroids, antipsychotics)</li> <li>• History of weight loss surgery</li> <li>• Participation in another weight management research study</li> <li>• Regain of &gt;3% of total body weight in the 2 months prior to study entry</li> <li>• Childbirth in the past 6 months</li> <li>• Claustrophobia, or any MRI incompatible implants</li> <li>• Pregnant or planning to become pregnant</li> <li>• Unable to consent</li> </ul>



Table 2. Study schedule of recruitment, treatment, and assessments as a function of time-points (according to the SPIRIT 2013 figure guidelines)

	DURATION OF THE STUDY				
	Recruitment	Baseline	Post-treatment (8 weeks)	Follow-up (6 months)	Follow-up (12 months)
TIME-POINT	$t_0$	$t_1$	$t_2$	$t_3$	$t_4$
<b>RECRUITMENT</b>					
Screening for inclusion/exclusion criteria	X				
Informed consent		X			
Assignment to treatment arms	X				
<b>TREATMENT</b>					
MBSR		X	X		
HLC		X	X		
<b>ASSESSMENT</b>					
SCID-IV	X				
fMRI		X	X		
Weight		X	X	X	X
Height (and BMI)		X	X	X	
Waist Circumference		X	X	X	
CES-D		X	X	X	
PSS-14		X	X	X	
STAI-T		X	X	X	
STAXI-II		X	X	X	
Satisfaction with Life		X	X	X	
Emotion Regulation Questionnaire		X	X	X	
Eating Behavior Inventory		X	X	X	
Internal Disinhibition Subscale of the Eating Inventory		X	X	X	
Paffenbarger Physical Activity Scale		X	X	X	
Pittsburgh Sleep Quality Index		X	X	X	



## REFERENCES

1. Ogden C, Carroll M. Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, Trends 1976-1980 Through 2007-2008. *CDC Natl Cent Heal Stat*. 2010.
2. Schroeder SA. We Can Do Better — Improving the Health of the American People. *N Engl J Med*. 2007;357(12):1221-1228. doi:10.1056/NEJMsa073350.
3. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet*. 2011;378(9793):815-825. doi:10.1016/S0140-6736(11)60814-3.
4. Renehan a G, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet*. 2008;371(1474-547X (Electronic)):569-578. doi:10.1016/S0140-6736(08)60269-X.
5. Kearns K, Dee A, Fitzgerald AP, Doherty E, Perry IJ. Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level. *BMC Public Health*. 2014;14:143. doi:10.1186/1471-2458-14-143.
6. Dombrowski SU, Knittle K, Avenell A, Araujo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. *BMJ*. 2014;348:g2646. doi:10.1136/bmj.g2646.
7. Marcus B, Williams D, Dubbert P, et al. What We Know and What We Need to Know: A Scientific Statement From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); Council on Cardiovascular Disease in the Young; and the Interdis. *Circulation*. 2006;114:2739-2752.
8. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? *Diabetes Care*. 2008;31 Suppl 2. doi:10.2337/dc08-s265.
9. Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. *Cochrane Database Syst Rev*. 2009;(1):CD003999. doi:10.1002/14651858.CD003999.pub3.
10. Merrill RM, Aldana SG, Greenlaw RL, Diehl H a, Salberg A, Englert H. Can newly acquired healthy behaviors persist? An analysis of health behavior decay. *Prev Chronic Dis*. 2008;5(1):A13. doi:A13 [pii].
11. Ory MG, Smith ML, Mier N, Wernicke MM. The science of sustaining health behavior change: The health maintenance consortium. *Am J Health Behav*. 2010;34(6):647-659. doi:10.1016/j.biotechadv.2011.08.021.Secreted.
12. Björntorp P, Rosmond R. Obesity and cortisol. In: *Nutrition*. Vol 16. ; 2000:924-936. doi:10.1016/S0899-9007(00)00422-6.

13. Lattimore P, Maxwell L. Cognitive load, stress, and disinhibited eating. *Eat Behav.* 2004;5(4):315-324. doi:10.1016/j.eatbeh.2004.04.009.
14. O'Connor DB, Jones F, Conner M, McMillan B, Ferguson E. Effects of daily hassles and eating style on eating behavior. *Health Psychol.* 2008;27(1 Suppl):S20-S31. doi:10.1037/0278-6133.27.1.S20.
15. Wallis DJ, Hetherington MM. Emotions and eating. Self-reported and experimentally induced changes in food intake under stress. *Appetite.* 2009;52(2):355-362. doi:10.1016/j.appet.2008.11.007.
16. Cosci F, Pistelli F, Lazzarini N, Carrozzi L. Nicotine dependence and psychological distress: outcomes and clinical implications in smoking cessation. *Psychol Res Behav Manag.* 2011;4:119-128. doi:10.2147/PRBM.S14243.
17. Elfhag K, Rössner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. *Obes Rev.* 2005;6(1):67-85. doi:10.1111/j.1467-789X.2005.00170.x.
18. Wing RR, Papandonatos G, Fava JL, et al. Maintaining large weight losses: the role of behavioral and psychological factors. *J Consult Clin Psychol.* 2008;76(6):1015-1021. doi:10.1037/a0014159.
19. Evers KE, Prochaska JO, Johnson JL, Mauriello LM, Padula J a, Prochaska JM. A randomized clinical trial of a population- and transtheoretical model-based stress-management intervention. *Heal Psychol.* 2006;25(4):521-529. doi:10.1037/0278-6133.25.4.521.
20. Mansyur CL, Pavlik VN, Hyman DJ, Taylor WC, Goodrick GK. Self-efficacy and barriers to multiple behavior change in low-income African Americans with hypertension. *J Behav Med.* 2013;36(1):75-85. doi:10.1007/s10865-012-9403-7.
21. Ng DM, Jeffery RW. Relationships between perceived stress and health behaviors in a sample of working adults. *Health Psychol.* 2003;22(6):638-642. doi:10.1037/0278-6133.22.6.638.
22. Benninghoven D, Kaduk A, Wiegand U, Specht T, Kunzendorf S, Jantschek G. Influence of anxiety on the course of heart disease after acute myocardial infarction - Risk factor or protective function? *Psychother Psychosom.* 2006;75(1):56-61. doi:10.1159/000089227.
23. Garipey G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. *Int J Obes.* 2010;34(3):407-419. doi:10.1038/ijo.2009.252.
24. Kuhl EA, Fauerbach JA, Bush DE, Ziegelstein RC. Relation of Anxiety and Adherence to Risk-Reducing Recommendations Following Myocardial Infarction. *Am J Cardiol.* 2009;103(12):1629-1634. doi:10.1016/j.amjcard.2009.02.014.
25. Castro Y, Kendzor DE, Businelle MS, et al. Structural and predictive equivalency of the Wisconsin smoking withdrawal scale across three racial/ethnic groups. *Nicotine Tob Res.*

- 2011;13(7):548-555. doi:10.1093/ntr/ntr039.
26. Kahler CW, Strong DR, Niaura R, Brown RA. Hostility in smokers with past major depressive disorder: relation to smoking patterns, reasons for quitting, and cessation outcomes. *Nicotine Tob Res.* 2004;6(5):809-818. doi:10.1080/1462220042000282546.
  27. Patterson F, Kerrin K, Wileyto EP, Lerman C. Increase in anger symptoms after smoking cessation predicts relapse. *Drug Alcohol Depend.* 2008;95(1-2):173-176. doi:10.1016/j.drugalcdep.2008.01.013.
  28. Ogedegbe GO, Boutin-Foster C, Wells MT, et al. A randomized controlled trial of positive-affect intervention and medication adherence in hypertensive African Americans. *Arch Intern Med.* 2012;172(4):322-326. doi:10.1001/archinternmed.2011.1307.
  29. Peterson JC, Charlson ME, Hoffman Z, et al. A randomized controlled trial of positive-affect induction to promote physical activity after percutaneous coronary intervention. *Arch Intern Med.* 2012;172(4):329-336. doi:10.1001/archinternmed.2011.1311.
  30. Kabat-Zinn J. Mindfulness-based interventions in context: Past, present, and future. *Clin Psychol Sci Pract.* 2003;10(2):144-156.
  31. Ouwens MA, Schiffer AA, Visser LI, Ræijmaekers NJC, Nyklíček I. Mindfulness and eating behaviour styles in morbidly obese males and females. *Appetite.* 2015;87:62-67. doi:10.1016/j.appet.2014.11.030.
  32. Goyal M, Singh S, Sibinga EMS, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. *JAMA Intern Med.* 2014;174(3):357-368. doi:10.1001/jamainternmed.2013.13018.
  33. Fulwiler C, Brewer JA, Sinnott S, Loucks EB. Mindfulness-Based Interventions for Weight Loss and CVD Risk Management. *Curr Cardiovasc Risk Rep.* 2015;9(10). doi:10.1007/s12170-015-0474-1.
  34. Mason AE, Lustig RH, Brown RR, et al. Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial. *Appetite.* 2015;91:311-320. doi:10.1016/j.appet.2015.04.062.
  35. Khoury B, Lecomte T, Fortin G, et al. Mindfulness-based therapy: A comprehensive meta-analysis. *Clin Psychol Rev.* 2013;33(6):763-771. doi:10.1016/j.cpr.2013.05.005.
  36. Roland LT, Lenze EJ, Hardin FM, et al. Effects of mindfulness based stress reduction therapy on subjective bother and neural connectivity in chronic tinnitus. *Otolaryngol - Head Neck Surg (United States).* 2015;152(5):919-926. doi:10.1177/0194599815571556.
  37. Kilpatrick LA, Suyenobu BY, Smith SR, et al. Impact of mindfulness-based stress reduction training on intrinsic brain connectivity. *Neuroimage.* 2011;56(1):290-298. doi:10.1016/j.neuroimage.2011.02.034.
  38. Taren AA, Gianaros PJ, Greco CM, et al. Mindfulness meditation training alters stress-related amygdala resting state functional connectivity: A randomized controlled trial. *Soc*

- Cogn Affect Neurosci.* 2014;10(12):1758-1768. doi:10.1093/scan/nsv066.
39. Creswell JD, Taren AA, Lindsay EK, et al. Alterations in resting state functional connectivity link mindfulness meditation with reduced interleukin-6: a randomized controlled trial. *Biol Psychiatry.* January 2016. doi:10.1016/j.biopsych.2016.01.008.
40. Katterman SN, Kleinman BM, Hood MM, Nackers LM, Corsica JA. Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: A systematic review. *Eat Behav.* 2014;15(2):197-204. doi:10.1016/j.eatbeh.2014.01.005.
41. Pbert L, Madison JM, Druker S, et al. Effect of mindfulness training on asthma quality of life and lung function: a randomised controlled trial. *Thorax.* 2012;67(9):769-776. doi:10.1136/thoraxjnl-2011-200253.
42. Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. *Magn Reson Med.* 1995;34(4):537-541. doi:10.1002/mrm.1910340409.
43. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. *Nat Rev Neurosci.* 2007;8(9):700-711. doi:nrn2201 [pii]n10.1038/nrn2201.
44. Liston C, McEwen BS, Casey BJ. Psychosocial stress reversibly disrupts prefrontal processing and attentional control. *Proc Natl Acad Sci U S A.* 2009;106(3):912-917. doi:10.1073/pnas.0807041106.
45. Lewis CM, Baldassarre A, Committeri G, Romani GL, Corbetta M. Learning sculpts the spontaneous activity of the resting human brain. *Proc Natl Acad Sci U S A.* 2009;106(41):17558-17563. doi:10.1073/pnas.0902455106.
46. Brewer JA, Worhunsky PD, Gray JR, Tang Y-Y, Weber J, Kober H. Meditation experience is associated with differences in default mode network activity and connectivity. *Proc Natl Acad Sci.* 2011;108(50):20254-20259. doi:10.1073/pnas.1112029108.
47. Kilpatrick LA, Suyenobu BY, Smith SR, et al. Impact of Mindfulness-Based Stress Reduction training on intrinsic brain connectivity. *Neuroimage.* 2011;56(1):290-298. doi:S1053-8119(11)00190-X [pii]10.1016/j.neuroimage.2011.02.034.
48. Shehzad Z, Kelly AMC, Reiss PT, et al. The resting brain: Unconstrained yet reliable. *Cereb Cortex.* 2009;19(10):2209-2229. doi:10.1093/cercor/bhn256.
49. Zuo XN, Kelly C, Adelstein JS, Klein DF, Castellanos FX, Milham MP. Reliable intrinsic connectivity networks: Test-retest evaluation using ICA and dual regression approach. *Neuroimage.* 2010;49(3):2163-2177. doi:10.1016/j.neuroimage.2009.10.080.
50. Radloff L. The CED-D scale: a self-report depression scale for research in the general population. *Appl Psychol Meas.* 1977;1(3):385-401. doi:10.1177/014662167700100306.
51. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc*

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Behav.* 1983;24(4):385-396. doi:10.2307/2136404.
52. Spielberger CD, Gorsuch RL, Lushene PR, Vagg PR, Jacobs AG. *Manual for the State-Trait Anxiety Inventory (Form Y).*; 1983.
53. Spielberger C. State-Trait Anger Expression Inventory-2, Professional Manual. *Psychol Assess Resour Inc.* 1999:1-7.
54. Diener E, Emmons R a, Larsen RJ, Griffin S. The Satisfaction With Life Scale. *J Pers Assess.* 1985;49(1):71-75. doi:10.1207/s15327752jpa4901\_13.
55. Gross JJ, John OP. Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. *J Pers Soc Psychol.* 2003;85(2):348-362. doi:10.1037/0022-3514.85.2.348.
56. Stunkard a. J, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. *J Psychosom Res.* 1985;29(1):71-83. doi:10.1016/0022-3999(85)90010-8.
57. Niemeier HM, Phelan S, Fava JL, Wing RR. Internal disinhibition predicts weight regain following weight loss and weight loss maintenance. *Obes (Silver Spring).* 2007;15(10):2485-2494. doi:15/10/2485 [pii]10.1038/oby.2007.295.
58. Paffenbarger Jr. RS, Blair SN, Lee IM, Hyde RT. Measurement of physical activity to assess health effects in free-living populations. *Med Sci Sport Exerc.* 1993;25(1):60-70.
59. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4.
60. Anthropometry procedures manual. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES).
61. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry.* 2000;31(2):73-86. doi:10.1016/S0005-7916(00)00012-4.
62. Baer R a, Smith GT, Lykins E, et al. Construct validity of the five facet mindfulness questionnaire in meditating and nonmeditating samples. *Assessment.* 2008;15(3):329-342. doi:10.1177/1073191107313003.
63. Cohen J. A power primer. *Psychol Bull.* 1992;112(1):155-159. doi:10.1037/0033-2909.112.1.155.
64. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. *Stat Med.* 1992;11(13):1685-1704. doi:10.1002/sim.4780111304.
65. Rabe-Hesketh S, Skrondal A. *Multilevel and Longitudinal Modeling Using Stata.* Vol 60.; 2006. doi:10.1198/tas.2006.s56.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
66. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol.* 1986;51(6):1173-1182.
67. MacKinnon DP. *Introduction to Statistical Mediation Analysis.*; 2008.
68. Talairach J, Tournoux P. *Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging.* Vol 39.; 1988. doi:10.1111/mono.12083.
69. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *Neuroimage.* 2002;15(4):870-878. doi:10.1006/nimg.2001.1037rS1053811901910377 [pii].
70. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage.* 2002;15(1):273-289.
71. Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL. A self-regulation program for maintenance of weight loss. *N Engl J Med.* 2006;355(15):1563-1571. doi:355/15/1563 [pii]10.1056/NEJMoa061883.



## APPENDIX

### World Health Organization Trial Registration Data Set information

1. Primary Registry and Trial Identifying Number: NCT02189187 (<http://clinicaltrials.gov>).
2. Date of Registration in Primary Registry: June 24, 2014
3. Secondary Identifying Numbers: n/a
4. Source(s) of Monetary or Material Support: see page 12
5. Primary Sponsor: Carl Fulwiler (see page 1)
6. Secondary Sponsor(s): n/a
7. Contact for Public Queries: Carl Fulwiler (see page 1)
8. Contact for Scientific Queries: Carl Fulwiler (see page 1)
9. Public Title: “Keeping Weight Off: Brain Changes Associated With Healthy Behaviors”
10. Scientific Title: “Mind and health: developing a neural marker for mindfulness, a pathway to health”
11. Countries of Recruitment: United States
12. Health Condition(s) or Problem(s) Studied: see Introduction section
13. Intervention(s): see Interventions section of Methods
14. Key Inclusion and Exclusion Criteria: see Table 1
15. Study Type: Randomized controlled trial with evenly distributed arms
16. Date of First Enrollment: January 8, 2015
17. Target Sample Size: 80 (see page 10)
18. Recruitment Status: Recruiting
19. Primary Outcome(s): see Assessments and Data Analysis sections
20. Key Secondary Outcomes: see Assessments and Data Analysis sections

### Other items from SPIRIT Checklist

3. Protocol version: 8; last modified July 1, 2015
- 21a, 22. The funding agency has determined that a full Data Safety Monitoring Board is not necessary for this study. Instead, any unexpected, serious, or intervention-related i.e. Serious Adverse Event (SAEs) will be reported to an Independent Monitoring Committee composed 3 scientists not involved in the study. This includes a senior biostatistician, an obesity research expert and clinician, and a senior neuroimaging researcher. Adverse events include possible health related risks such as MRI discomfort, psychological distress during the Interventions, imminent subject’s risk during SCID interview or detecting structural brain image at baseline. Anticipated or unrelated AEs will be reported to the Independent Monitoring Committee, the IRB, and the NIH in accordance with their requirements. In the semi-annual SAE summary, the Independent Monitoring Committee will provide a review of each SAE, including relevant information forwarded by the study team, and verify that he has reviewed all serious adverse event reports.
23. The funding agency conducts annual on-site reviews of study procedures and progress.
- 31c. We will provide supplemental access to the requisite data, workflows and results, as well as provide maximum data availability to reuse in future meta-analyses and data pooling efforts. In addition, we will make all data available at the end of the award period via a NIH-funded NITRC (Neuroimaging Informatics Tools and Resources Clearinghouse - [nitrc.org](http://nitrc.org)) project. We will release the data under the Creative Commons, Attribution-NonCommercial-Share Alike License.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 2 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Appendix ___
Protocol version	3	Date and version identifier	___ Appendix ___
Funding	4	Sources and types of financial, material, and other support	___ 12 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 11 ___
	5b	Name and contact information for the trial sponsor	___ 1 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 11, 12 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ n/a ___

1  
2  
3 **Introduction**  
4

5 Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	_____4-7_____
6 rationale		studies (published and unpublished) examining benefits and harms for each intervention	
7			
8	6b	Explanation for choice of comparators	_____6, 7_____
9			
10 Objectives	7	Specific objectives or hypotheses	_____6, 7_____
11			
12 Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
13		allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	_____7, 8_____
14			

15  
16 **Methods: Participants, interventions, and outcomes**  
17

18 Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	_____7, 8_____
19		be collected. Reference to where list of study sites can be obtained	
20			
21 Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	_____7, 8, 13_____
22		individuals who will perform the interventions (eg, surgeons, psychotherapists)	
23			
24 Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	_____9_____
25		administered	
26			
27	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	_____7_____
28		change in response to harms, participant request, or improving/worsening disease)	
29			
30	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	_____7_____
31		(eg, drug tablet return, laboratory tests)	
32			
33	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	_____7, 8, 13_____
34			
35 Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	_____7-9_____
36		pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
37		median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
38		efficacy and harm outcomes is strongly recommended	
39			
40			
41 Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	_____Figure 1_____
42		participants. A schematic diagram is highly recommended (see Figure)	
43			
44			
45			

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___10___
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___8___

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___8___
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___8___
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___8___
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___8, 10, 11___
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___n/a___

**Methods: Data collection, management, and analysis**

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___8-10___
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___7___

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___10___
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___10, 11___
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___10, 11___
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___10___
13				
14				
15				
16	<b>Methods: Monitoring</b>			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___Appendix___
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___n/a___
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___Appendix___
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___Appendix___
30				
31				
32				
33	<b>Ethics and dissemination</b>			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___11___
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___n/a___
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___7___
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___n/a___
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___10___
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___11___
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___n/a___
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___n/a___
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___11___
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	___11___
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___Appendix___
29				
30	<b>Appendices</b>			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary Material
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___n/a___
36				
37				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.



# BMJ Open

## Keeping Weight Off: Study Protocol of a RCT to Investigate Brain Changes Associated with Mindfulness-Based Stress Reduction

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-012573.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Sep-2016
Complete List of Authors:	Fulwiler, Carl; University of Massachusetts Medical School, Center for Mindfulness Siegel, Julia; University of Massachusetts Medical School Allison, Jeroan; University of Massachusetts Medical School, Quantitative Health Sciences Rosal, Milagros; University of Massachusetts Medical School, Medicine Brewer, Judson; University of Massachusetts Medical School, Center for Mindfulness King, Jean; University of Massachusetts Medical School
<b>Primary Subject Heading</b>:	Complementary medicine
Secondary Subject Heading:	Medical management
Keywords:	mindfulness, weight loss, behavior change maintenance, neuroimaging

SCHOLARONE™  
Manuscripts

Only

**TITLE PAGE**

Keeping Weight Off: Study Protocol of a RCT to Investigate Brain Changes Associated with Mindfulness-Based Stress Reduction

Carl Fulwiler<sup>1</sup>, Julia A. Siegel<sup>2</sup>, Jeroan Allison<sup>3</sup>, Milagros C. Rosal<sup>4</sup>, Judson Brewer<sup>1</sup>, Jean A. King<sup>5</sup>

<sup>1</sup> University of Massachusetts Medical School, Departments of Psychiatry and Medicine and Center for Mindfulness

<sup>2</sup> University of Massachusetts Medical School

<sup>3</sup> University of Massachusetts Medical School, Department of Quantitative Health Sciences

<sup>4</sup> University of Massachusetts Medical School, Department of Medicine

<sup>5</sup> University of Massachusetts Medical School, Departments of Psychiatry, Neurology and Radiology

**Corresponding Author (Primary Sponsor):**

Carl Fulwiler, MD, PhD

Center for Mindfulness

University of Massachusetts Medical School

222 Maple Avenue

Shrewsbury, MA 01545

Email: [carl.fulwiler@umassmed.edu](mailto:carl.fulwiler@umassmed.edu)

Phone: +1 508-856-8389

Fax: +1 508-856-1977

**Keywords:**

mindfulness; Mindfulness Based Stress Reduction; weight loss; behavior change maintenance; resting state functional connectivity; neuroimaging

## ABSTRACT

### Introduction:

Obesity is a growing epidemic fueled by unhealthy behaviors and associated with significant comorbidities and financial costs. While behavioral interventions produce clinically meaningful weight loss, weight loss maintenance is challenging. This may partially be due to failure to target stress and emotional reactivity. Mindfulness-Based Stress Reduction (MBSR) reduces stress and emotional reactivity and may be a useful tool for behavior change maintenance. This study seeks to provide a mechanistic understanding for clinical trials of the benefits of MBSR for weight loss maintenance by examining changes in functional connectivity and the association of these changes with clinical outcomes.

### Methods and analysis:

Community-dwelling individuals (n=80) who intentionally lost  $\geq 5\%$  of their body weight in the past year will be recruited and randomized to an MBSR program or educational control. Functional connectivity (FC) using resting state functional MRI (fMRI) will be measured at baseline and 8 weeks. Psychological factors, health behaviors, body mass index (BMI), and waist circumference will be measured at baseline, 8 weeks, and 6 months post-intervention. A 12-month telephone follow-up will assess self-reported weight. Analyses will characterize FC changes in response to MBSR in comparison to a control condition, assess the relationship between baseline FC status and pre-post MBSR changes in FC, and investigate the association of FC change with changes in psychological factors and weight loss maintenance.

### Ethics and dissemination:

The University of Massachusetts Medical School Institutional Review Board has approved this study, Declaration of Helsinki protocols are being followed, and patients will give written informed consent. The Independent Monitoring Committee will monitor protocol adherence. Results from the study will be disseminated to the medical community at conferences and submitted for publication in peer-reviewed journals when the last patient included has been followed up for 12 months.

**Trial registration number:** NCT02189187 (<http://clinicaltrials.gov>).

## ARTICLE SUMMARY

### Strengths and limitations of this study

- This is a timely and innovative study that will advance the field of mindfulness research and increase understanding of its mechanisms of action, setting the stage for a comprehensive clinical trial.
- The intervention is low-risk, highly accessible, low-cost, and is implemented in a real world clinical population and community setting. The control course was specifically designed to serve as an attention control for MBSR.
- The cost of a neuroimaging biomarker could be considered a limitation for large-scale clinical trials, but the insights about neural mechanisms of change cannot be obtained with other methods.

## INTRODUCTION

Unhealthy behaviors such as overeating and sedentary lifestyles are major contributors to cardiovascular disease, cancer, type 2 diabetes and other chronic conditions. They have produced a rapid rise in obesity that threatens to reverse recent gains in life expectancy<sup>1</sup> and accounts for a large percentage of premature deaths in the U.S.<sup>2</sup> The number of obese adults in the U.S. is expected to rise by 65 million from 2010 to 2030, resulting in a predicted additional 6–8 million cases of diabetes, 5–6.8 million cases of heart disease and stroke, and over 400,000 cancer cases.<sup>3</sup> For each 5kg/m<sup>2</sup> increase in BMI, the risks of esophageal cancer and colon cancer in men increase by 52% and 24%, respectively, and the risks of endometrial cancer, gall bladder cancer, and breast cancer in women increase by 59%, 59%, and 12%, respectively.<sup>4</sup>

In addition to significant morbidity, obesity has a substantial financial impact due to both health care costs and decreased productivity. Obesity-related U.S. health care costs were \$2.5 trillion in 2009 and are predicted to rise by at least \$22 billion/year by 2020 and \$48 billion/year by 2030.<sup>3</sup>

Weight loss is vital for reducing these extensive health and economic burdens; and even minimal weight loss has a meaningful impact. In an overweight and obese population in Ireland, a 1kg/m<sup>2</sup> decrease in BMI led to 26 fewer cases of chronic disease per 1,000 men and 28 fewer cases per 1,000 women.<sup>5</sup> Similarly, a 1% decrease in BMI across the U.S. population (1kg weight loss for the average adult) is predicted to prevent 2.1–2.4 million cases of diabetes, 1.4–1.7 million cases of cardiovascular disease, and 73,000–127,000 cancer cases; and would only require reducing caloric intake by 20 kcal per day for 3 years.<sup>3</sup>

Current obesity treatments include lifestyle modification, pharmacotherapy, and surgical options. A systematic review of various approaches to weight loss maintenance found that behavioral interventions involving both food intake and physical activity led to significant, albeit small, improvements in weight loss maintenance at 12 months after the intervention.<sup>6</sup> Exercise programs alone, however, may be most effective in the adoption phase.<sup>7</sup> Similarly, certain medications such as orlistat and sibutramine facilitate weight loss but commonly only work short-term when used alone, and may have unfavorable side effects.<sup>8</sup> Bariatric surgery can be effective long-term, but it can be associated with perioperative surgical risks and weight regain is common.<sup>8</sup> Also, many patients are unwilling or ineligible to undergo surgery.

Many interventions are effective for initiating weight loss and other health behavior changes, but they have shown only limited ability to affect significant, long-term behavior change in the majority of adults.<sup>7,9–11</sup> In part this may be attributable to a failure of existing interventions to adequately address the effects of stress and emotional reactivity on relapse to unhealthy behaviors and failure to maintain long-term behavior change. Perceived stress and symptoms of emotional reactivity (depression, anxiety, anger) are linked to unhealthy lifestyle behaviors<sup>12–15</sup> and predict worse outcomes in maintenance studies.<sup>16–18</sup> Indeed, studies of health behavior change have demonstrated that perceived stress<sup>19–21</sup> and indices of emotional reactivity such as anxiety,<sup>22–24</sup> depression, and anger<sup>25–27</sup> are associated with poor outcomes. In contrast, positive affect is associated with improved outcomes.<sup>28,29</sup>

1  
2  
3 Mindfulness, defined as paying attention to one's inner and outer experiences in a non-  
4 judgmental manner from moment to moment,<sup>30</sup> has been associated with healthy behaviors.  
5 Dispositional mindfulness in obese patients awaiting bariatric surgery was found to be positively  
6 associated with a restrained eating style (using restrictive control over food to lose weight) but  
7 negatively associated with emotional (eating in response to emotional states) and external eating  
8 behaviors (eating in response to external cues). Mindfulness may discourage external eating by  
9 increasing sensitivity to hunger and satiety such that these internal cues guide behavior instead.  
10 In addition, mindfulness may prevent emotional eating by encouraging acceptance of negative  
11 feelings, lowering stress, and thus promoting distinction between emotion and hunger. Finally,  
12 mindfulness has been shown to decrease impulsivity which may reduce unhealthy eating  
13 behaviors.<sup>31</sup>  
14  
15  
16

17  
18 Several mindfulness-based or mindfulness-associated practices are promising agents of behavior  
19 change, but we need to understand their neural mechanisms in order to optimize their use.  
20 Mindfulness-Based Stress Reduction (MBSR) is a psycho-educational program that teaches  
21 emotional and physical self-care. Participants receive training in formal and informal  
22 mindfulness practices and learn about the role of good nutrition, rest, and exercise, as well as the  
23 role played by thoughts and emotions in physical and emotional health. They are taught how to  
24 cultivate a non-reactive awareness of mental and physical experience in an effort to increase self-  
25 efficacy and reduced emotional reactivity—leading to healthier lifestyle practices. A recent  
26 comparative effectiveness review found moderately strong evidence for mindfulness meditation  
27 programs, particularly MBSR, for anxiety, depression and pain compared to nonspecific active  
28 controls, and weaker evidence for stress and health-related quality of life.<sup>32</sup> Evidence is mixed  
29 regarding the effectiveness of mindfulness-based interventions on weight loss, at least with  
30 relatively short follow-up periods.<sup>33</sup> Whether MBSR can support maintenance of weight loss  
31 following successful initiation of health behavior change warrants investigation based on its  
32 ability to lower emotional and behavioral reactivity to stress and negative emotions, risk risk  
33 factors for relapse to unhealthy behaviors. Importantly, an understanding of neural targets and  
34 mechanisms of change is necessary for specifying for whom mindfulness is likely to work and  
35 for optimizing the intervention for maximal effectiveness. Mindfulness may work better in  
36 specific subpopulations, as seen in a group of women with specific endogenous opioidergic  
37 activity who were found to be more receptive to mindfulness training in an effort to decrease  
38 pleasure eating.<sup>34</sup> Additionally, efficacy of mindfulness-based therapy has been strongly  
39 positively associated with dispositional mindfulness of participants and therapists.<sup>35</sup>  
40 Neuroimaging, specifically resting state functional MRI (fMRI), is a powerful approach to  
41 identifying mechanisms of change for MBSR involving the role of emotion regulation in  
42 maintenance of health behavior change.  
43  
44  
45  
46  
47

48  
49 Neuroimaging studies report an association between MBSR and changes in functional  
50 connectivity (FC) that may reflect improved attention, sensory processing, and reflective  
51 awareness of sensory experience.<sup>36,37</sup> Mindfulness has also been shown to alter resting state FC  
52 of the amygdala, a region involved in physiological stress response. A randomized controlled  
53 trial found that a three-day intensive mindfulness training reversed the effects of stress on the  
54 amygdala-subgenual anterior cingulate cortex in a group of stressed unemployed adults in the  
55 community.<sup>38</sup> This mindfulness training was also shown to increase resting state FC between the  
56 default mode network and the left dorsolateral prefrontal cortex, an area involved in top-down  
57  
58  
59  
60



executive control.<sup>39</sup> However, no previous studies have examined how mindfulness training affects the neural circuitry of emotion regulation in a weight loss sample and little is known about mechanisms of behavior change in people undergoing mindfulness training.

### Gaps in knowledge

Emerging evidence suggests that mindfulness may be helpful for changing behaviors such as overeating<sup>40</sup> but the mechanistic knowledge of how mindfulness facilitates behavior change is not known. Efforts to fill this gap could enhance our ability to identify likely “responders” and thus optimize intervention efforts, consistent with current trends towards personalized medicine approaches. Specifically, we are lacking knowledge of specific neural targets of mindfulness training to inform clinical trials of health behavior change and maintenance of change. In addition, data on long-term outcomes of mindfulness training is lacking.

Understanding the neural mechanisms that link MBSR to changes in emotional regulation and behavior are a critical next step in tapping the potential of MBSR as an intervention for behavior change and maintenance. A validated biomarker will allow investigators to monitor fidelity of intervention delivery, adherence, and dose-response in clinical trials. If validated as a biomarker, changes in FC will allow future studies to determine characteristics of individuals who are most responsive to MBSR and which components of the mindfulness intervention are most active, and may enable development of a more compact and potent intervention. FC may also help identify subsets of high-risk patients that would benefit from specific tailoring of the intervention. It is worth noting that if clinical trials prove that MBSR prevents weight regain, MRIs would not be required in a larger dissemination study or as the intervention is deployed in a large-scale public health approach.

### Study aims and hypotheses

To characterize FC, psychological, behavioral, and anthropometric changes in response to MBSR and the comparison condition, we will randomize a sample of 80 participants who have intentionally lost  $\geq 5\%$  of their body weight during the previous year to MBSR or an attention control specifically designed to be structurally equivalent to MBSR. Study aims and hypotheses are as follows.

Our first primary aim is to characterize FC changes in response to MBSR and the comparison condition. We hypothesize that participants randomized to the MBSR condition will experience greater increases in FC from baseline to post-intervention (Hypothesis 1); and participants with higher baseline FC will show less change in response to MBSR (Hypothesis 2).

Our second primary aim is to investigate the association of FC change with changes in psychological factors and maintenance of weight loss at 8 weeks and 6-month follow-up. We hypothesize that increases in FC will be associated with improvement in depressive symptoms (Hypothesis 3) and inversely related to decreased weight (BMI) and total waist circumference (Hypothesis 4).

Our third primary aim is to assess **changes in BMI at 6 & 12 months to obtain preliminary measures of effect size and variability by study group for future clinical trials.**

As secondary aims, we will use mediation analysis to determine how change in FC is explained by 1) class attendance, 2) self-reported time in homework practice, 3) self-reported time for each specific component of the multifaceted training program, and 4) trait mindfulness. An exploratory aim is to examine correlations of change in FC with changes in additional psychological factors (perceived stress, trait anger, trait anxiety, positive affect) and health behaviors (healthy eating, physical activity, sleep quality).

## METHODS

### Study design

The “Keeping Weight Off” study is a randomized, prospective, two-armed, controlled trial. A sample of 80 participants from the community, who have intentionally lost at least 5% of their body weight during the previous year, will be equally randomized into two groups: an MBSR program and a Healthy Living Course (HLC)—an attention control specifically designed to be structurally equivalent to MBSR.<sup>41</sup> The HLC uses the same format of 8-weekly classes lasting 2 1/2 hours, and controls for attention and other nonspecific factors including staff interactions, psychoeducation about health and stress management, classroom format, homework, group process, and data collection.<sup>41</sup> Our main outcome measures are resting-state FC, depression symptoms, BMI, and waist circumference. FC, psychological factors, health behaviors, BMI, and waist circumference will be measured at baseline and 8 weeks. Psychological factors, health behaviors, BMI, and waist circumference will also be measured at 6 months. In addition, a telephone follow-up will be attempted on participants at 12 months to assess weight.

Total planned enrollment is 80 participants. Screening for eligibility criteria, baseline visits, and follow-up visits will take place at University of Massachusetts Medical School (UMMS), Worcester, Massachusetts. All MBSR classes will be conducted at the UMMS Center for Mindfulness in Shrewsbury, Massachusetts.

### Study participants

We will recruit participants who range in age from 25 to 60 (chosen to minimize age-related changes in FC), have intentionally lost  $\geq 5\%$  of their body weight during the previous year, and are motivated to maintain this weight loss. Individuals will be excluded if they have participated in an MBSR course, regular meditation practice, or any other form of meditative practice (such as yoga, Tai Chi or contemplative prayer), for more than an average of 20 minutes per week within the past 2 years. Full inclusion and exclusion criteria are listed in Table 1.

Eligible participants will proceed with the baseline visit prior to randomization, including collection of demographic information about age, education, marital status, occupation, and current employment status, followed by questionnaires and fMRI scan. The full study schedule of recruitment, treatment, and assessments is described in Table 2. All participants will provide informed consent. This process will be conducted by the study coordinator in person prior to the baseline visit, following the protocol established by the University of Massachusetts Institutional Review Board (IRB). Study staff will keep in touch with participants regarding attendance and homework completion and provide support and encouragement to continue with the intervention if participants express dissatisfaction. Participants who drop out of the intervention will be asked to return for all follow-up visits to complete all outcome data collection.

## Study recruitment

Recruitment will be conducted using advertising in the community (internet, flyers and social media) of Worcester County, which has a population of over 800,000, as well as a two-stage process to recruit outpatients from the UMass Memorial Medical Center using the electronic medical record. The largest health care system in Central and Western Massachusetts, the medical center has a large population from which to draw, with nearly 70,000 patient visits for primary care alone, and a Weight Center sees that sees nearly 1000 new patients per year. Our team has an excellent record of recruitment and retention in our previous of overweight/obese subjects using these methods.

First, with a HIPAA waiver authorization a search query will be conducted with basic eligibility criteria, and secondly identified records will be reviewed to exclude causes of weight loss such as serious illness or weight loss medications. Web-based and telephone screening will determine whether they meet inclusion criteria. Further screening will be done in person to gather a medical history and complete the Structured Clinical Interview for DSM-IV (SCID) to exclude participants with a serious psychiatric, cognitive or medical disorder or a history of alcohol or substance abuse or dependence in the past 6 months.

## Randomization and study blinding

Study participants will be equally randomized to either the MBSR intervention arm or HLC arm based on a permuted blocks randomization scheme. In this procedure, treatment allocations will be made within blocks so that the numbers assigned to each arm are equal after each block has been filled. Blocks of various sizes (2, 4, 6) will be used in random order, to facilitate allocation concealment, that is, to make it nearly impossible to determine the treatment assignment based on a pattern of previous treatment allocations. Randomization will be implemented using sealed envelopes by the study coordinator who will be the only member of the research team who is not blind to treatment assignment. A unique identification number will help to endure that blindness is maintained throughout the study. All members of the research team involved in data analysis will be blind to treatment assignment.

To address the possibility that an imbalanced distribution of baseline FC could mask important findings, we will employ a non-stratified permuted-block randomized design with an interim analysis of the distribution of baseline FC. If important imbalances are found, we will implement recruitment strategies to increase enrollment of participants who have baseline FC with a specified range combined with covariate-adaptive randomization techniques. Residual imbalances will be addressed with post-hoc statistical adjustment.

## Assessments

### *Resting state functional connectivity*

In contrast to task-evoked functional and effective connectivity studies, resting-state fMRI enables examination of the brain's intrinsic functional connections in the absence of externally controlled stimuli or tasks.<sup>42,43</sup> FC is responsive to changing levels of stress,<sup>44</sup> intense training on a task,<sup>45</sup> and recently, meditation practice including MBSR.<sup>46,47</sup> FC has been shown to have remarkable consistency and moderate to high test-test reliability over periods of months to a year as well.<sup>48,49</sup> All MRI's will be acquired on the 3T scanner (Philips Achieva) in the UMMS

Advanced MRI Center. 3D high-resolution structural T1-weighted MR images will be obtained to provide anatomical landmarks. Following the structural imaging, resting-state fMRI data will be collected. Participants will be instructed to remain relaxed with eye closed as fMRI images are continuously collected for 10 mins. The duration of the entire MRI procedure will be 30 min.

### *Psychological symptoms*

The Center for Epidemiologic Studies Depression Scale (CES-D)<sup>50</sup> depression symptom score is a primary outcome. Additional outcomes include perceived stress, anxiety, anger, positive affect, and emotion regulation, which will be assessed using the following measures respectively: the Perceived Stress Scale (PSS-14),<sup>51</sup> the State-Trait Anxiety Inventory – trait version (STAI-T),<sup>52</sup> the State-Trait Anger Expression Inventory (STAXI-II) trait anger subscale,<sup>53</sup> the Satisfaction with Life Scale<sup>54</sup> and the Emotion Regulation Questionnaire.<sup>55</sup>

### *Health behaviors*

Health behaviors will be assessed using the Eating Behavior Inventory,<sup>56</sup> the Internal Disinhibition Subscale of the Eating Inventory,<sup>57</sup> the Paffenbarger Physical Activity Scale,<sup>58</sup> and the Pittsburgh Sleep Quality Index (PSQI),<sup>59</sup> respectively.

### *Anthropometrics*

Procedures are adapted from the CDC's Anthropometry Procedures Manual.<sup>60</sup> For the measurement of height and weight, the Seca 213 Portable stadiometer and the TANITA, BWB-800 electronic scale will be used and measurements will be taken twice and averaged to assure reliability. Measurement of waist circumference will be taken directly on the skin using measuring tape placed just above top of the iliac crest on each side.

### **Potential mediators and confounds**

Intervention engagement will be assessed with class attendance and a home practice log. Treatment expectancy and credibility will be assessed with the Credibility/Expectancy Questionnaire CEQ<sup>61</sup> modified slightly to substitute the word “Class” for “Therapy” in the instructions. Secondary analyses will examine how change in FC is explained by 1) class attendance, 2) self-reported time in homework practice, 3) self-reported time for each specific component of the multifaceted training program, and 4) trait mindfulness as measured by the Five Facet Mindfulness Questionnaire (FFMQ).<sup>62</sup>

### **Interventions**

#### *Experimental Condition: Mindfulness-Based Stress Reduction (MBSR)*

MBSR, described above, is taught in eight weekly classes and one all-day retreat. Homework assignments include formal meditation practices and informal practices during daily life. Classroom activities teach formal meditation practices including sitting meditation, body scan, mindful yoga, walking meditation). Participants also learn to bring awareness in the present moment to aspects of daily life and apply this practice to stressful experiences in order to avoid reflexive or conditioned reactions. The goal of MBSR is to provide participants with these skills for lifelong self-management.

The MBSR classes are taught by certified teachers from the UMass Center for Mindfulness. All teachers have completed the rigorous training and certification for MBSR through the Center for

1  
2  
3 Mindfulness. To further assure fidelity each class will be reviewed in weekly sessions with a co-  
4 investigator. In addition, the principal investigators will routinely convene the entire clinical  
5 research team to monitor the overall fidelity of the MBSR intervention.  
6  
7

#### 8 *Attention control: Healthy Living Course*

9 The Healthy Living Course (HLC) was specifically designed to serve as a control condition for  
10 MBSR.<sup>41</sup> HLC consists of 8 weekly 2-hour classes. Sessions consist of lectures and discussion  
11 on the following topics: healthy living, healthy eating, physical activity and health, sleep and  
12 health, stress management, time management, and unhealthy behaviors (smoking, drinking). The  
13 HLC is designed to control for attention and other nonspecific factors including staff  
14 interactions, psychoeducation about health and stress management, classroom format,  
15 homework, group process, and data collection.<sup>41</sup>  
16  
17  
18

#### 19 **Data collection**

20 Electronic data capture (EDC, REDCap<sup>TM</sup>) will be used for all data collection except imaging.  
21 Surveys for psychological symptoms, health behaviors, and potential mediators and confounds  
22 are programmed into the EDC system. During research visits, participants will enter survey  
23 responses directly into this system and research staff will enter screening and anthropometric  
24 data with periodic checks for quality assurance. All data will be maintained in a secure location  
25 accessible only to study personnel. For MRI measures, data will be analyzed blind to  
26 intervention group by two fMRI experts who perform cross-validity checks.  
27  
28

#### 29 **Data analysis and sample size considerations**

30 We based the study sample size on Hypothesis 1, powered to detect an effect size of 0.32  
31 standard deviations. This moderate Cohen effect size<sup>63</sup> represents differential over-time change  
32 for the intervention versus comparison group cast in standard deviation units. The study design  
33 calls for a baseline measurement and two follow-up measurements. In addition, we assumed a  
34 two-tailed alpha error of 0.05, and a within-person correlation for over-time measurement of  
35 0.8.<sup>64</sup> With these assumptions, 40 participants in each group are needed for 80% power. We will  
36 enroll 100 participants (50 randomized to each arm) and allow for up to 20% loss to follow up,  
37 for an effective sample size of 80.  
38  
39  
40

41 Statistical analysis will begin with univariate summaries of data distributions and examination of  
42 longitudinal trends with graphic displays. Bivariate associations will then be examined using the  
43 chi-square test, ANOVA, and the Spearman correlation test. Hypotheses 1 and 2 focus on over-  
44 time differences between the two study groups, while Hypotheses 2 and 3 focus on over-time  
45 differences for the combined sample. Hypotheses will be formally tested using generalized linear  
46 mixed models that represent the clustering of observations within participants as a random  
47 intercept, adopt an appropriate link and distribution for the specific outcome, and parameterize  
48 the intervention effect as a group-time intervention, when appropriate.<sup>65</sup> To preserve the power  
49 of randomization, hypothesis testing will be performed on an intent-to-treat basis. As a  
50 secondary aim, mediation analysis will determine how change in FC is explained by markers of  
51 intervention adherence using techniques as described by MacKinnon.<sup>66,67</sup> Sensitivity analyses  
52 with multiple imputation with chained equations will address missing data.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Imaging data is preprocessed using Statistical Parametric Mapping (SPM8) software (Wellcome Department of Cognitive Neurology, London, UK) running under the MATLAB environment (Mathworks, Inc., Sherborn, MA). The data is initially corrected for motion (threshold of 2 mm). Further pre-processing of the data includes a) slice scan time correction, b) spatial smoothing using a 3D Gaussian filter (4-mm FWHM), and c) voxel-wise linear detrending and 0.01-0.08Hz band-pass filtering. Structural and functional data of each participant is then be transformed to standard stereotaxic space<sup>68</sup> to facilitate group analysis.

Following the preprocessing steps, FC will be generated using correlational analysis. Left and right amygdala are used as separate seed regions of interest (ROI). FC maps from each individual seed will then be calculated for each individual subject using Resting-State fMRI Data Analysis Toolkit (REST, <http://www.restfmri.net>). Each seed ROI will be evaluated using two-way repeated measures ANOVA on a voxel-by-voxel basis (factors: group and imaging day) at the threshold of  $p < 0.05$  after accounting for multiple comparisons using the criteria of false discovery rate (FDR).<sup>69</sup> Voxels with significantly changed FC within each ROI will then be averaged to generate the FC change for the ROI. This procedure will yield a single value of amygdala-orbitofrontal FC for each participant at each point in time. All ROI definitions are based on Automated Anatomical Labeling (AAL)<sup>70</sup> built in the MarsBAR toolbox of SPM8. Image analysis will be done blind to group membership.

As a secondary analysis, we will explore FC changes in other brain networks following MBSR using other seed regions. For example, other cortical regions that have been implicated in modulation of limbic reactivity (e.g. anterior cingulate) will be examined using a hypothesis-driven approach.

### **Ethical considerations and dissemination plans**

This study is approved by the University of Massachusetts Medical School IRB and registered as a national clinical trial (NCT02189187), Declaration of Helsinki protocols are being followed, and patients will give written informed consent. Protocol adherence will be monitored by the Independent Monitoring Committee (for full WHO Trial Registration Data Set information see Appendix). Results from the study will be disseminated to the medical community at conferences and submitted for publication in peer-reviewed journals when the last patient included has been followed up for 12 months. Negative and inconclusive as well as positive results will be published or made publicly available through the study website [www.umassmed.edu/keepingweightoff](http://www.umassmed.edu/keepingweightoff).

### **AUTHORS' CONTRIBUTIONS**

CF conceptualized the study, and JAK, JA, MR and JB participated in the study design. CF, JAK, and JAS collected data. CF and JAS wrote and all authors revised the article and approved the final version to be published.

### **COMPETING INTERESTS**

All authors declare no conflicts of interest.

### **ACKNOWLEDGEMENTS**



1  
2  
3 The authors thank Dr. Nanyin Zhang and Dr. Wei Huang for technical assistance with study  
4 design. We also extend our sincere gratitude to Dr. Saki Santorelli, Executive Director of the  
5 Center for Mindfulness at the University of Massachusetts Medical School, for his support and  
6 contributions, and the staff and teachers of the Center for Mindfulness for their assistance. The  
7 project was conducted at the UMMS Advanced MR Imaging Center with support from Dr.  
8 Shaokuan Zheng.  
9  
10

### 11 **FUNDING**

12 The National Center for Complementary and Integrative Health (NCCIH)) provided funding for  
13 this trial (grants R34AT006963 and R34 AT006963-01A1 to CF and JAK). The design of this  
14 trial was reviewed and approved by NCCIH's Office of Clinical and Regulatory Affairs. Support  
15 was also provided by an award from the UMMS Department of Radiology. The content is solely  
16 the responsibility of the authors and does not necessarily represent the official views of the  
17 National Institutes of Health or the UMMS Department of Radiology Advanced MR Imaging  
18 Center.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TABLES

Table 1. Eligibility criteria

<u>Inclusion criteria:</u>	<u>Exclusion criteria:</u>
<ul style="list-style-type: none"> <li>• Males and females</li> <li>• Right or left handed</li> <li>• Ages 25-60</li> <li>• Intentionally lost <math>\geq 5\%</math> of body weight during the previous year</li> <li>• Intending to maintain weight loss</li> <li>• BMI &gt; 25 kg/m<sup>2</sup> in the past 2 years and greater than 20.5 kg/m<sup>2</sup> at time of study entry</li> <li>• Under the care of a primary care physician for at least the last year prior to screening</li> <li>• Able to communicate by telephone with research staff</li> <li>• Have a healthcare provider, personal trainer or weight-loss counselor who can complete and sign a form indicating the amount and timing of their weight loss OR have a dated photograph or weight loss diary.<sup>71</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Weight &gt;300lbs (limitation of MRI scanner)</li> <li>• Prior participation in an MBSR course</li> <li>• Regular meditation practice (or any other form of meditative practice, such as yoga, Tai Chi, or contemplative prayer) for more than an average of 20 min/week within the past 2 years</li> <li>• Serious psychiatric, cognitive, or medical disorder</li> <li>• Alcohol/substance abuse or dependence in past 6 months</li> <li>• Any conditions that are incompatible with MRI</li> <li>• Structural brain damage as determined by an independent neuroradiologist, based on T1W 3D TFE sagittal and T1W FFE axial images</li> <li>• History of an eating disorder, diabetes mellitus or medications for diabetes mellitus</li> <li>• Medication that affects weight (weight loss medications, corticosteroids, antipsychotics)</li> <li>• History of weight loss surgery</li> <li>• Participation in another weight management research study</li> <li>• Regain of &gt;3% of total body weight in the 2 months prior to study entry</li> <li>• Childbirth in the past 6 months</li> <li>• Claustrophobia, or any MRI incompatible implants</li> <li>• Pregnant or planning to become pregnant</li> <li>• Unable to consent</li> </ul>

Table 2. Study schedule of recruitment, treatment, and assessments as a function of time-points (according to the SPIRIT 2013 figure guidelines)

	DURATION OF THE STUDY				
	Recruitment	Baseline	Post-treatment (8 weeks)	Follow-up (6 months)	Follow-up (12 months)
TIME-POINT	$t_0$	$t_1$	$t_2$	$t_3$	$t_4$
<b>RECRUITMENT</b>					
Screening for inclusion/exclusion criteria	X				
Informed consent		X			
Assignment to treatment arms	X				
<b>TREATMENT</b>					
MBSR		X	X		
HLC		X	X		
<b>ASSESSMENT</b>					
SCID-IV	X				
fMRI		X	X		
Weight		X	X	X	X
Height (and BMI)		X	X	X	
Waist Circumference		X	X	X	
CES-D		X	X	X	
PSS-14		X	X	X	
STAI-T		X	X	X	
STAXI-II		X	X	X	
Satisfaction with Life		X	X	X	
Emotion Regulation Questionnaire		X	X	X	
Eating Behavior Inventory		X	X	X	
Internal Disinhibition Subscale of the Eating Inventory		X	X	X	
Paffenbarger Physical Activity Scale		X	X	X	
Pittsburgh Sleep Quality Index		X	X	X	

## REFERENCES

1. Ogden C, Carroll M. Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, Trends 1976-1980 Through 2007-2008. *CDC Natl Cent Heal Stat*. 2010.
2. Schroeder SA. We Can Do Better — Improving the Health of the American People. *N Engl J Med*. 2007;357(12):1221-1228. doi:10.1056/NEJMsa073350.
3. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet*. 2011;378(9793):815-825. doi:10.1016/S0140-6736(11)60814-3.
4. Renehan a G, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet*. 2008;371(1474-547X (Electronic)):569-578. doi:10.1016/S0140-6736(08)60269-X.
5. Kearns K, Dee A, Fitzgerald AP, Doherty E, Perry IJ. Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level. *BMC Public Health*. 2014;14:143. doi:10.1186/1471-2458-14-143.
6. Dombrowski SU, Knittle K, Avenell A, Araujo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. *BMJ*. 2014;348:g2646. doi:10.1136/bmj.g2646.
7. Marcus B, Williams D, Dubbert P, et al. What We Know and What We Need to Know: A Scientific Statement From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity); Council on Cardiovascular Disease in the Young; and the Interdis. *Circulation*. 2006;114:2739-2752.
8. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? *Diabetes Care*. 2008;31 Suppl 2. doi:10.2337/dc08-s265.
9. Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. *Cochrane Database Syst Rev*. 2009;(1):CD003999. doi:10.1002/14651858.CD003999.pub3.
10. Merrill RM, Aldana SG, Greenlaw RL, Diehl H a, Salberg A, Englert H. Can newly acquired healthy behaviors persist? An analysis of health behavior decay. *Prev Chronic Dis*. 2008;5(1):A13. doi:A13 [pii].
11. Ory MG, Smith ML, Mier N, Wernicke MM. The science of sustaining health behavior change: The health maintenance consortium. *Am J Health Behav*. 2010;34(6):647-659. doi:10.1016/j.biotechadv.2011.08.021.Secreted.
12. Björntorp P, Rosmond R. Obesity and cortisol. In: *Nutrition*. Vol 16. ; 2000:924-936. doi:10.1016/S0899-9007(00)00422-6.

13. Lattimore P, Maxwell L. Cognitive load, stress, and disinhibited eating. *Eat Behav.* 2004;5(4):315-324. doi:10.1016/j.eatbeh.2004.04.009.
14. O'Connor DB, Jones F, Conner M, McMillan B, Ferguson E. Effects of daily hassles and eating style on eating behavior. *Health Psychol.* 2008;27(1 Suppl):S20-S31. doi:10.1037/0278-6133.27.1.S20.
15. Wallis DJ, Hetherington MM. Emotions and eating. Self-reported and experimentally induced changes in food intake under stress. *Appetite.* 2009;52(2):355-362. doi:10.1016/j.appet.2008.11.007.
16. Cosci F, Pistelli F, Lazzarini N, Carrozzi L. Nicotine dependence and psychological distress: outcomes and clinical implications in smoking cessation. *Psychol Res Behav Manag.* 2011;4:119-128. doi:10.2147/PRBM.S14243.
17. Elfhag K, Rössner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. *Obes Rev.* 2005;6(1):67-85. doi:10.1111/j.1467-789X.2005.00170.x.
18. Wing RR, Papandonatos G, Fava JL, et al. Maintaining large weight losses: the role of behavioral and psychological factors. *J Consult Clin Psychol.* 2008;76(6):1015-1021. doi:10.1037/a0014159.
19. Evers KE, Prochaska JO, Johnson JL, Mauriello LM, Padula J a, Prochaska JM. A randomized clinical trial of a population- and transtheoretical model-based stress-management intervention. *Heal Psychol.* 2006;25(4):521-529. doi:10.1037/0278-6133.25.4.521.
20. Mansyur CL, Pavlik VN, Hyman DJ, Taylor WC, Goodrick GK. Self-efficacy and barriers to multiple behavior change in low-income African Americans with hypertension. *J Behav Med.* 2013;36(1):75-85. doi:10.1007/s10865-012-9403-7.
21. Ng DM, Jeffery RW. Relationships between perceived stress and health behaviors in a sample of working adults. *Health Psychol.* 2003;22(6):638-642. doi:10.1037/0278-6133.22.6.638.
22. Benninghoven D, Kaduk A, Wiegand U, Specht T, Kunzendorf S, Jantschek G. Influence of anxiety on the course of heart disease after acute myocardial infarction - Risk factor or protective function? *Psychother Psychosom.* 2006;75(1):56-61. doi:10.1159/000089227.
23. Garipey G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. *Int J Obes.* 2010;34(3):407-419. doi:10.1038/ijo.2009.252.
24. Kuhl EA, Fauerbach JA, Bush DE, Ziegelstein RC. Relation of Anxiety and Adherence to Risk-Reducing Recommendations Following Myocardial Infarction. *Am J Cardiol.* 2009;103(12):1629-1634. doi:10.1016/j.amjcard.2009.02.014.
25. Castro Y, Kendzor DE, Businelle MS, et al. Structural and predictive equivalency of the Wisconsin smoking withdrawal scale across three racial/ethnic groups. *Nicotine Tob Res.*

- 2011;13(7):548-555. doi:10.1093/ntr/ntr039.
26. Kahler CW, Strong DR, Niaura R, Brown RA. Hostility in smokers with past major depressive disorder: relation to smoking patterns, reasons for quitting, and cessation outcomes. *Nicotine Tob Res.* 2004;6(5):809-818. doi:10.1080/1462220042000282546.
  27. Patterson F, Kerrin K, Wileyto EP, Lerman C. Increase in anger symptoms after smoking cessation predicts relapse. *Drug Alcohol Depend.* 2008;95(1-2):173-176. doi:10.1016/j.drugalcdep.2008.01.013.
  28. Ogedegbe GO, Boutin-Foster C, Wells MT, et al. A randomized controlled trial of positive-affect intervention and medication adherence in hypertensive African Americans. *Arch Intern Med.* 2012;172(4):322-326. doi:10.1001/archinternmed.2011.1307.
  29. Peterson JC, Charlson ME, Hoffman Z, et al. A randomized controlled trial of positive-affect induction to promote physical activity after percutaneous coronary intervention. *Arch Intern Med.* 2012;172(4):329-336. doi:10.1001/archinternmed.2011.1311.
  30. Kabat-Zinn J. Mindfulness-based interventions in context: Past, present, and future. *Clin Psychol Sci Pract.* 2003;10(2):144-156.
  31. Ouwens MA, Schiffer AA, Visser LI, Ræijmaekers NJC, Nyklíček I. Mindfulness and eating behaviour styles in morbidly obese males and females. *Appetite.* 2015;87:62-67. doi:10.1016/j.appet.2014.11.030.
  32. Goyal M, Singh S, Sibinga EMS, et al. Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. *JAMA Intern Med.* 2014;174(3):357-368. doi:10.1001/jamainternmed.2013.13018.
  33. Fulwiler C, Brewer JA, Sinnott S, Loucks EB. Mindfulness-Based Interventions for Weight Loss and CVD Risk Management. *Curr Cardiovasc Risk Rep.* 2015;9(10). doi:10.1007/s12170-015-0474-1.
  34. Mason AE, Lustig RH, Brown RR, et al. Acute responses to opioidergic blockade as a biomarker of hedonic eating among obese women enrolled in a mindfulness-based weight loss intervention trial. *Appetite.* 2015;91:311-320. doi:10.1016/j.appet.2015.04.062.
  35. Khoury B, Lecomte T, Fortin G, et al. Mindfulness-based therapy: A comprehensive meta-analysis. *Clin Psychol Rev.* 2013;33(6):763-771. doi:10.1016/j.cpr.2013.05.005.
  36. Roland LT, Lenze EJ, Hardin FM, et al. Effects of mindfulness based stress reduction therapy on subjective bother and neural connectivity in chronic tinnitus. *Otolaryngol - Head Neck Surg (United States).* 2015;152(5):919-926. doi:10.1177/0194599815571556.
  37. Kilpatrick LA, Suyenobu BY, Smith SR, et al. Impact of mindfulness-based stress reduction training on intrinsic brain connectivity. *Neuroimage.* 2011;56(1):290-298. doi:10.1016/j.neuroimage.2011.02.034.
  38. Taren AA, Gianaros PJ, Greco CM, et al. Mindfulness meditation training alters stress-related amygdala resting state functional connectivity: A randomized controlled trial. *Soc*



- Cogn Affect Neurosci.* 2014;10(12):1758-1768. doi:10.1093/scan/nsv066.
39. Creswell JD, Taren AA, Lindsay EK, et al. Alterations in resting state functional connectivity link mindfulness meditation with reduced interleukin-6: a randomized controlled trial. *Biol Psychiatry.* January 2016. doi:10.1016/j.biopsych.2016.01.008.
40. Katterman SN, Kleinman BM, Hood MM, Nackers LM, Corsica JA. Mindfulness meditation as an intervention for binge eating, emotional eating, and weight loss: A systematic review. *Eat Behav.* 2014;15(2):197-204. doi:10.1016/j.eatbeh.2014.01.005.
41. Pbert L, Madison JM, Druker S, et al. Effect of mindfulness training on asthma quality of life and lung function: a randomised controlled trial. *Thorax.* 2012;67(9):769-776. doi:10.1136/thoraxjnl-2011-200253.
42. Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. *Magn Reson Med.* 1995;34(4):537-541. doi:10.1002/mrm.1910340409.
43. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. *Nat Rev Neurosci.* 2007;8(9):700-711. doi:nrn2201 [pii]n10.1038/nrn2201.
44. Liston C, McEwen BS, Casey BJ. Psychosocial stress reversibly disrupts prefrontal processing and attentional control. *Proc Natl Acad Sci U S A.* 2009;106(3):912-917. doi:10.1073/pnas.0807041106.
45. Lewis CM, Baldassarre A, Committeri G, Romani GL, Corbetta M. Learning sculpts the spontaneous activity of the resting human brain. *Proc Natl Acad Sci U S A.* 2009;106(41):17558-17563. doi:10.1073/pnas.0902455106.
46. Brewer JA, Worhunsky PD, Gray JR, Tang Y-Y, Weber J, Kober H. Meditation experience is associated with differences in default mode network activity and connectivity. *Proc Natl Acad Sci.* 2011;108(50):20254-20259. doi:10.1073/pnas.1112029108.
47. Kilpatrick LA, Suyenobu BY, Smith SR, et al. Impact of Mindfulness-Based Stress Reduction training on intrinsic brain connectivity. *Neuroimage.* 2011;56(1):290-298. doi:S1053-8119(11)00190-X [pii]10.1016/j.neuroimage.2011.02.034.
48. Shehzad Z, Kelly AMC, Reiss PT, et al. The resting brain: Unconstrained yet reliable. *Cereb Cortex.* 2009;19(10):2209-2229. doi:10.1093/cercor/bhn256.
49. Zuo XN, Kelly C, Adelstein JS, Klein DF, Castellanos FX, Milham MP. Reliable intrinsic connectivity networks: Test-retest evaluation using ICA and dual regression approach. *Neuroimage.* 2010;49(3):2163-2177. doi:10.1016/j.neuroimage.2009.10.080.
50. Radloff L. The CED-D scale: a self-report depression scale for research in the general population. *Appl Psychol Meas.* 1977;1(3):385-401. doi:10.1177/014662167700100306.
51. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc*

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Behav.* 1983;24(4):385-396. doi:10.2307/2136404.
52. Spielberger CD, Gorsuch RL, Lushene PR, Vagg PR, Jacobs AG. *Manual for the State-Trait Anxiety Inventory (Form Y).*; 1983.
53. Spielberger C. State-Trait Anger Expression Inventory-2, Professional Manual. *Psychol Assess Resour Inc.* 1999:1-7.
54. Diener E, Emmons R a, Larsen RJ, Griffin S. The Satisfaction With Life Scale. *J Pers Assess.* 1985;49(1):71-75. doi:10.1207/s15327752jpa4901\_13.
55. Gross JJ, John OP. Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. *J Pers Soc Psychol.* 2003;85(2):348-362. doi:10.1037/0022-3514.85.2.348.
56. Stunkard a. J, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. *J Psychosom Res.* 1985;29(1):71-83. doi:10.1016/0022-3999(85)90010-8.
57. Niemeier HM, Phelan S, Fava JL, Wing RR. Internal disinhibition predicts weight regain following weight loss and weight loss maintenance. *Obes (Silver Spring).* 2007;15(10):2485-2494. doi:15/10/2485 [pii]10.1038/oby.2007.295.
58. Paffenbarger Jr. RS, Blair SN, Lee IM, Hyde RT. Measurement of physical activity to assess health effects in free-living populations. *Med Sci Sport Exerc.* 1993;25(1):60-70.
59. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4.
60. Anthropometry procedures manual. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES).
61. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry.* 2000;31(2):73-86. doi:10.1016/S0005-7916(00)00012-4.
62. Baer R a, Smith GT, Lykins E, et al. Construct validity of the five facet mindfulness questionnaire in meditating and nonmeditating samples. *Assessment.* 2008;15(3):329-342. doi:10.1177/1073191107313003.
63. Cohen J. A power primer. *Psychol Bull.* 1992;112(1):155-159. doi:10.1037/0033-2909.112.1.155.
64. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. *Stat Med.* 1992;11(13):1685-1704. doi:10.1002/sim.4780111304.
65. Rabe-Hesketh S, Skrondal A. *Multilevel and Longitudinal Modeling Using Stata.* Vol 60.; 2006. doi:10.1198/tas.2006.s56.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
66. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. *J Pers Soc Psychol.* 1986;51(6):1173-1182.
67. MacKinnon DP. *Introduction to Statistical Mediation Analysis.*; 2008.
68. Talairach J, Tournoux P. *Co-Planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging.* Vol 39.; 1988. doi:10.1111/mono.12083.
69. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *Neuroimage.* 2002;15(4):870-878. doi:10.1006/nimg.2001.1037rS1053811901910377 [pii].
70. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage.* 2002;15(1):273-289.
71. Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL. A self-regulation program for maintenance of weight loss. *N Engl J Med.* 2006;355(15):1563-1571. doi:355/15/1563 [pii]10.1056/NEJMoa061883.

## APPENDIX

### World Health Organization Trial Registration Data Set information

1. Primary Registry and Trial Identifying Number: NCT02189187 (<http://clinicaltrials.gov>).
2. Date of Registration in Primary Registry: June 24, 2014
3. Secondary Identifying Numbers: n/a
4. Source(s) of Monetary or Material Support: see page 12
5. Primary Sponsor: Carl Fulwiler (see page 1)
6. Secondary Sponsor(s): n/a
7. Contact for Public Queries: Carl Fulwiler (see page 1)
8. Contact for Scientific Queries: Carl Fulwiler (see page 1)
9. Public Title: “Keeping Weight Off: Brain Changes Associated With Healthy Behaviors”
10. Scientific Title: “Mind and health: developing a neural marker for mindfulness, a pathway to health”
11. Countries of Recruitment: United States
12. Health Condition(s) or Problem(s) Studied: see Introduction section
13. Intervention(s): see Interventions section of Methods
14. Key Inclusion and Exclusion Criteria: see Table 1
15. Study Type: Randomized controlled trial with evenly distributed arms
16. Date of First Enrollment: January 8, 2015
17. Target Sample Size: 80 (see page 10)
18. Recruitment Status: Recruiting
19. Primary Outcome(s): see Assessments and Data Analysis sections
20. Key Secondary Outcomes: see Assessments and Data Analysis sections

### Other items from SPIRIT Checklist

3. Protocol version: 8; last modified July 1, 2015
- 21a, 22. The funding agency has determined that a full Data Safety Monitoring Board is not necessary for this study. Instead, any unexpected, serious, or intervention-related i.e. Serious Adverse Event (SAEs) will be reported to an Independent Monitoring Committee composed 3 scientists not involved in the study. This includes a senior biostatistician, an obesity research expert and clinician, and a senior neuroimaging researcher. Adverse events include possible health related risks such as MRI discomfort, psychological distress during the Interventions, imminent subject’s risk during SCID interview or detecting structural brain image at baseline. Anticipated or unrelated AEs will be reported to the Independent Monitoring Committee, the IRB, and the NIH in accordance with their requirements. In the semi-annual SAE summary, the Independent Monitoring Committee will provide a review of each SAE, including relevant information forwarded by the study team, and verify that he has reviewed all serious adverse event reports.
23. The funding agency conducts annual on-site reviews of study procedures and progress.
- 31c. We will provide supplemental access to the requisite data, workflows and results, as well as provide maximum data availability to reuse in future meta-analyses and data pooling efforts. In addition, we will make all data available at the end of the award period via a NIH-funded NITRC (Neuroimaging Informatics Tools and Resources Clearinghouse - [nitrc.org](http://nitrc.org)) project. We will release the data under the Creative Commons, Attribution-NonCommercial-Share Alike License.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 2 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Appendix ___
Protocol version	3	Date and version identifier	___ Appendix ___
Funding	4	Sources and types of financial, material, and other support	___ 12 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 11 ___
	5b	Name and contact information for the trial sponsor	___ 1 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 11, 12 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ n/a ___

1				
2				
3	<b>Introduction</b>			
4				
5	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	___4-7___
6	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
7				
8		6b	Explanation for choice of comparators	___6, 7___
9				
10	Objectives	7	Specific objectives or hypotheses	___6, 7___
11				
12	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
13			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	___7, 8___
14				
15				
16	<b>Methods: Participants, interventions, and outcomes</b>			
17				
18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	___7, 8___
19			be collected. Reference to where list of study sites can be obtained	
20				
21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	___7, 8, 13___
22			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
23				
24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	___9___
25			administered	
26				
27		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	___7___
28			change in response to harms, participant request, or improving/worsening disease)	
29				
30		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	___7___
31			(eg, drug tablet return, laboratory tests)	
32				
33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	___7, 8, 13___
34				
35	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	___7-9___
36			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
37			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
38			efficacy and harm outcomes is strongly recommended	
39				
40				
41	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	___Table 2___
42			participants. A schematic diagram is highly recommended (see Figure)	
43				
44				
45				
46				
47				
48				
49				



1				
2				
3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___10___
4				
5				
6	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___8___
7				

### 8 **Methods: Assignment of interventions (for controlled trials)**

#### 9 Allocation:

10				
11				
12	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___8___
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___8___
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___8___
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___8, 10, 11___
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___n/a___
29				
30				
31				

### 32 **Methods: Data collection, management, and analysis**

33				
34	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___8-10___
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___7___
40				
41				
42				
43				
44				
45				

1				
2				
3	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___ 10 ___
4				
5				
6				
7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ 10, 11 ___
8				
9				
10		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___ 10, 11 ___
11				
12		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___ 10 ___
13				
14				
15				
16	<b>Methods: Monitoring</b>			
17				
18	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___ Appendix ___
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___ n/a ___
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___ Appendix ___
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___ Appendix ___
30				
31				
32				
33	<b>Ethics and dissemination</b>			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___ 11 ___
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___ n/a ___
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1				
2				
3	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___7___
4				
5				
6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___n/a___
7				
8				
9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___10___
10				
11				
12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___11___
13				
14				
15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___n/a___
16				
17				
18	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___n/a___
19				
20				
21	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___11___
22				
23				
24				
25				
26		31b	Authorship eligibility guidelines and any intended use of professional writers	___11___
27				
28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___Appendix___
29				
30	<b>Appendices</b>			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary Material
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___n/a___
36				
37				

38 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 39 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 40 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 41